id	label	content
test_0	0	"This is a shared visit for services provided by me, ***** ***** *****, MD. I performed a face-to-face encounter with the patient and the following portion of the note is my own.      Impression: Metastatic ER negative, HER2 negative breast cancer on nab paclitaxel and pembrolizumab for     ***** ***** presents today for follow up ,she is is doing well and but has clinical or radiological evidence of progression for which she is to be treated with chemo-immunotherapy for her MSI high  metastatic disease.  o    The imaging studies were reviewed today and compared to prior scans.   Labs are in range for continuation of treatment     Plan:   Continue  with therapy until progression or intolerable side effects  Imaging guided by symptoms or every 3-4 months, longer intervals if stable.       .      This is a shared visit for services provided by Dr. ***** and myself.    SUBJECTIVE    ***** ***** is a 44 y.o. female with Lynch syndrome with early stage colon cancer and endometrial cancer and newly diagnosed metastatic breast cancer to liver and nodes. She started pembrolizumab and abraxane on 03/11/19 and presents today for cycle 1 day 8.    At today's visit she reports worsening GERD. Prilosec helps. Taking prn. Also reports nausea for which ativan works well.     She reports fatigue for 3 days after treatment.    She reports right axillary pain to shoulder blade on the right, much better since last week! Also right lumbosacral pain is stable. She reports new aching in her arms and legs. Continues flexeril and MS contin as well as oxycodone prn.    She reports numbness/tingling in toes and fingertips that is transient. She also reports leg cramping at night.    Off xarelto still since recent biopsy- was on it for non-occlusive jugular clot.     ROS  Constitutional: Negative for fever, chills, diaphoresis, appetite change, fatigue and unexpected weight change.   HENT: Negative for hearing loss, nosebleeds, 
 congestion, sore throat, mouth sores, neck pain, sinus pressure, or tinnitus.    Eyes: Negative for photophobia, pain, discharge, redness, itching and visual disturbance.   Respiratory: Negative for apnea, cough, chest tightness, shortness of breath, wheezing.   Cardiovascular: Negative for chest pain, palpitations and leg swelling.   Gastrointestinal: Negative for nausea, vomiting, abdominal pain, diarrhea, constipation, blood in stool, or abdominal distention.   Genitourinary: Negative for dysuria, urgency, frequency, hematuria, vaginal bleeding or discharge or difficulty urinating.   Musculoskeletal: Negative for myalgias, back pain, joint swelling, or arthralgias.   Skin: Negative for itching or rash.   Neurological: Negative for neuropathy, dizziness, tremors, seizures, syncope, speech difficulty, weakness, light-headedness, numbness or  headaches.   Hematological: Negative for adenopathy. Does not bruise/bleed easily.   Psychiatric/Behavioral: Negative for suicidal ideas, sleep disturbance, decreased concentration.   Remaining systems were reviewed and are negative.    Patient Active Problem List    Diagnosis Date Noted    Lynch syndrome 02/23/2019    Colon cancer (HCC) 02/23/2019    Metastatic breast cancer (HCC) 02/22/2019     Early stage breast cancer 2014  clinical Stage IIB (cT2 cN1 cM0) -> ypT1c(m) ypN1a (1/22 LN positive) triple negative invasive ductal carcinoma   s/p neoadjuvant ddAC + 5/12 weekly cycles of carboplatin/paclitaxel (discontinued due to poor tolerance) with disease progression while on carboplatin/paclitaxel   s/p partial mastectomy in February 2014   S/p adjuvant RT *****/*****-*****/*****,    Breast cancer local recurrence 2018  March 2018 biopsy proven recurrence of TNBC in the R chest wall   Genetic testing performed prior to the colon biopsy was negative for BRCA 1/2.     She had a pelvic US for pain 04/01/18 showing: 11mm EMS 2.4cm countor abnormality in the myometrium, 1.4cm complex right 
 ovarian cyst, left 4.7cm septated cyst in left adnexa, poss hydrosalpinx.      Colon cancer  PET/CT for complete restaging showed no evidence of distant metastases but revealed a hypermetabolic focus at the splenic flexure, which was biopsied on 05/25/18 and showed a primary colon adenocarcinoma with mucinous differentiation and nuclear loss of MSH2 and MSH6 by IHC.   Germline mutation testing positive for MSH2 mutation. Lynch syndrome panel (blood): 5 genes were analyzed: EPCAM, MLH1, MSH2, MSH6, and PMS2. Positive for: MSH2 c.1906G>C (p.Ala636Pro)  05/25/18 Colonoscopy performed which showed a 3cm descending colon polyp s/p polypectomy: primary colon adenocarcinoma with mucinous features with loss of MSH2, MSH6 -> s/p transverse colectomy in June 2018 -> Stage I (pT2 pN0), no chemotherapy or radiation   --Brain MRI negative for metastases    Uterine cancer  PET/CT also showed some hypermetabolic activity in the uterus and workup is ongoing.   TVUS/pelvic US: No uterine masses to correspond to hypermetabolic activity (likely physiological), cyst c/f hydrosalpinx identified. + irregular vaginal bleeding  s/p endometrial biopsy on 06/30/18 with pathology showing well-differentiated endometrioid adenocarcinoma       Overall diagnosis currently:  Diagnoses:  1) July 2013: R breast invasive ductal carcinoma, ER-/PR-/Her2- (TNBC), grade 3  *****BRCA testing not performed as insurance did not approve  2) March 2018: Recurrence of ER-/PR-/Her2- breast cancer in R chest wall   *****Genetic testing 05/19/18: Negative for BRCA 1/2, ATM, CDH1,CHEK2, PALB2, PTEN, STK11, TP53  3) May 2018: Splenic flexure moderately differentiated colon adenocarcinoma showing mucinous differentiation; *****loss of MSH2, MSH6  --> Final Surgical Pathology showed poorly differentiated signet ring cell carcinoma, TVA, negative for high-grade dysplasia   *****Lynch syndrome panel (blood): 5 genes were analyzed: EPCAM, MLH1, MSH2, MSH6, and PMS2. Positive for: MSH2 c.1906G>C (p.Ala636Pro)  4) Endometrioid adenocarcinoma, well-differentiated, FIGO 1      April 2018 - November 2018 gemcitabine + carboplatin: good clinical response in pectoral lymph nodes    Metastatic breast cancer  PET/CT 01/27/19:   1. Ill-defined right pectoralis soft tissue mass with internal calcifications: 1.2 x 2.4 cm (series 4 1 image 64) with a maximum SUV of 4.6.  2. Right subpectoral lymph node: 0.7 cm in short axis (series 4 1 image 69) with maximum SUV of 4.8.  3. Hypoenhancing caudate lobe lesion: 1.9 x 1.5 cm (series 4 1 image 29) with a maximum SUV of 16.1.   4. Lytic S1 vertebral body lesion: maximum SUV of 6.6.  Lymph nodes: Index nodes as described above. Additional hypermetabolic right internal mammary node is 0.6 x 0.8 cm (series 4 1 image 75 with a maximum SUV of 4.3.  The hypermetabolic caudate lobe lesion is markedly increased in size when compared to prior CT abdomen/pelvis from 09/29/2018. Additional hypoattenuating, hypermetabolic segment VII lesion is 1.3 x 1.7 x 1.5 cm  with a maximum SUV of 11.2  02/25/19 Liver biopsy: triple negative metastatic breast cancer      Vaginal bleeding 09/28/2018    DVT (deep venous thrombosis) (HCC) 08/31/2018     Left Subclavian DVT diagnosed 05/16/18. Dye study demonstrated complete occlusion of the brachiocephalic vein - now s/p Mediport removal on 08/04/18 on rivaroxaban 20mg PO daily.        Endometrial carcinoma (HCC) 08/26/2018     Added automatically from request for surgery *****           MEDICATIONS  Current Outpatient Medications   Medication Sig Dispense Refill    albuterol 90 mcg/actuation metered dose inhaler Inhale 2 puffs into the lungs every 4 (four) hours as needed.      AMBIEN CR 12.5 mg ER tablet nightly at bedtime.      brimonidine (MIRVASO) 0.33 % GEL Apply topically Daily.       cyclobenzaprine (FLEXERIL) 5 mg tablet Take 5 mg by mouth 3 (three) times daily as needed.      LORazepam (ATIVAN) 1 mg tablet Take 1 tablet (1 mg total) by 
 mouth every 6 (six) hours as needed for Anxiety. 30 tablet 3    morphine (MS CONTIN) 15 mg 12 hr ER tablet Take 15 mg by mouth Twice a day.      oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. 20 tablet 0    traMADol (ULTRAM) 50 mg tablet Take 1 tablet every 8 hours as needed for pain      acetaminophen (TYLENOL) 500 mg tablet Take 2 tablets (1,000 mg total) by mouth every 6 (six) hours. (Patient not taking: Reported on 02/22/2019) 60 tablet 0    esomeprazole (NEXIUM) 20 mg capsule Take 20 mg by mouth daily as needed.       LORazepam (ATIVAN) 0.5 mg tablet Take 0.5 mg by mouth every 12 (twelve) hours as needed.      naloxone 4 mg/actuation SPRAYNAERO Spray entire dose into 1 nostril for suspected overdose. If no response in 2-3 minutes, use new nasal spray for 2nd dose in other nostril.      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth daily as needed (constipation). (Patient not taking: Reported on 02/22/2019)      polyethylene glycol (MIRALAX) 17 gram packet Take 1 packet (17 g total) by mouth Daily. (Patient not taking: Reported on 03/17/2019) 510 g 11    prochlorperazine (COMPAZINE) 10 mg tablet Take 10 mg by mouth every 6 (six) hours as needed.      prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 03/17/2019) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth every morning. Starting in 1 week, 10/07/18. DO NOT TAKE THIS MEDICATION FROM *****/*****-*****/***** (Patient not taking: Reported on 03/17/2019)      simethicone (MYLICON) 80 mg chewable tablet Take 80 mg by mouth every 6 (six) hours as needed.      simethicone (MYLICON) 80 mg chewable tablet Take 1 tablet (80 mg total) by mouth every 4 (four) hours as needed for Flatulence. (Patient not taking: Reported on 
 03/17/2019) 100 tablet 2     No current facility-administered medications for this visit.        ALLERGIES  Allergies/Contraindications   Allergen Reactions    Penicillins Anaphylaxis     Puffy and itching,       Puffy and itching,           Adhesive Tape-Silicones      Other reaction(s): Rash    Haemophilus Influenzae      Other reaction(s): Unknown H1N1  Get puffy and injection site itchiness     Get puffy and injection site itchiness         Hydrochlorothiazide      Other reaction(s): Swelling    Hydroxychloroquine      Other reaction(s): Rash  Pt states she got a total body skin rash with hives needing prednisone to resolve and was told to stop taking it      Pt states she got a total body skin rash with hives needing prednisone to resolve and was told to stop taking it          Ibuprofen      Other reaction(s): Swelling  As per patient elevated BP     As per patient elevated BP            PAST, FAMILY, and SOCIAL HISTORY  Past Medical History:   Diagnosis Date    Asthma     mild, rarely uses her inhaler.      Bipolar disorder (HCC)     Breast cancer (HCC)     Depression     DVT (deep venous thrombosis) (HCC)     L subclavian    Hepatitis C     treated *****-*****.    History of chemotherapy     Hypertension     not on any meds at the moment, bp controlled.    Personal history of irradiation, presenting hazards to health      Family History   Problem Relation Name Age of Onset    Leukemia Mother          as a child, in remission    Other (Other) Mother          hysterectomy ?ovaries, 40s or 50s, s/p lacerated liver and liver transplant     No Known Problems Father          no health information known about paternal family    No Known Problems Brother          maternal half-brother, no health information known    No Known Problems Maternal Uncle      Colon cancer Maternal Grandmother          diagnosed 40s, mets to lung? deceased 70s    Uterine cancer Maternal Grandmother      Breast cancer 
 Maternal Grandmother      No Known Problems Brother          maternal half-brother, no health information known    No Known Problems Son          22    No Known Problems Son          18    No Known Problems Daughter 16     Social History     Tobacco Use    Smoking status: Former Smoker     Packs/day: 1.00     Years: 33.00     Pack years: 33.00     Types: Cigarettes     Last attempt to quit: 12/01/2017     Years since quitting: 1.2    Smokeless tobacco: Never Used   Substance and Sexual Activity    Alcohol use: Not Currently    Drug use: Yes     Types: Marijuana       PHYSICAL EXAM  ECOG 0  Vital Signs:  BP 116/75  | Pulse 75  | Temp 36.8 C (98.2 F) (Oral)  | Resp 16  | Ht 166 cm (5' 5.35"") Comment: December 2018 | Wt 86.5 kg (190 lb 12.8 oz)  | LMP 06/22/2018  | SpO2 98%  | BMI 31.41 kg/m   Constitutional:  WDWN, NAD.  Skin: warm, moist. No rashes or lesions.  Eyes: sclera anicteric, PERRL, EOMI.   HENT: sinuses nontender, nasal mucosa intact, pharynx without erythema, no thrush.   Lymph Nodes: no cervical, supraclavicular, or axillary lymphadenopathy.    Respiratory: BL lungs CTA, resonant to percussion, no wheezes, rhonchi, or crackles  Cardiovascular: normal heart rate, normal rhythm, no murmurs, no edema  Breast: no masses  GI: bowel sounds normal, soft, nontender, no distention, no organomegaly   Musculoskeletal: no point tenderness over bones or joints   Neurologic: alert & oriented x 3, no focal motor or sensory deficits  Psychiatric: mood stable    RESULTS  I have personally reviewed and interpreted the following:         ASSESSMENT & PLAN  ***** ***** is a 44 y.o. female with Lynch syndrome with early stage colon cancer and endometrial cancer and newly diagnosed metastatic breast cancer to liver and nodes. She started pembrolizumab and abraxane on 03/11/19 and presents today for cycle 1 day 8.    Metastatic breast cancer  - axillary pain improved which is hopeful for early treatment 
 response  - Continue abraxane every week (continuous) and Pembrolizumab every 3 weeks. Monitor TSH  - Due to poor peripheral access she will need a port, hopefully she can get it next week    Jugular clot  - restart xarelto, stop for port placement per IR    Colon cancer    Endometrial cancer    Nausea/GERD due to chemo  - Continue ativan and compazine prn. Allergic to zofran  - Rx prilosec 40mg qd    Peripheral neuropathy due to Taxane, new and mild  - Monitor    Mylagias due to Taxane  - Rx mag oxide 400mg qhs    Pain  - Continue work with pain mgmt  - Continue MS Contin 15mg BID, oxycodone prn, flexeril, and ativan  - continue stool softener to prevent opioid induced constipation    F/u 2 weeks then every 3 weeks      I have reviewed and updated the patient's past medical history, medications, allergies, family and social histories. I spent a total of 45 minutes face-to-face with the patient and 40 minutes of that time was spent counseling regarding the treatment plan, symptoms and therapeutic options. Patient expresses understanding and agrees with the plan.  
"
test_1	1	"FOLLOW UP VISIT    Ms. ***** is a 73 y.o. female whom I am seeing as a video visit at the UCSF Comprehensive Cancer Center for follow-up of her locally advanced pancreatic cancer.    Oncologic History:  07/08/19: Presented to UCSF ED with decreased PO intake, epigastric abdominal discomfort, new dx diabetes with A1C 10.  Workup included a CT AP with contrast with showed: 3.1x2.1cm ill defined mass in pancreatic body with upstream PD dilation, tail atrophy, encasement of celiac axis, CHA, proximal splenic        artery and at least abutment of the portal splenic confluence which is moderately narrowed.  Mildly enlarged gastrohepatic and periportal LN up to 1.5cm, hepatic steatosis  08/02/19: Initial consultation with Dr. ***** who recommended and EUS with biopsy and staging CT panc protocol  09/09/19: EUS (Dr. *****, UCSF): Pancreatic tail mass measuring at least 23.6 mm by 18.2 mm with FNB results show malignancy no preliminary cytology. The mass invaded into the main pancreatic duct causing pancreatic duct dilation and splenic vein. The mass abutted the celiac artery without clear invasion and encased the SMV.   09/24/19: CT AP Pancreatic Protocol: 4.1x3.4cm hypoenhancing mass involving pancreatic body measuring 4.1x3.4cm, completely encasing celiac axis, SMA, SMV, splenic artery and splenic vein. Portacaval and pericaval LAD. No ascites.    09/24/19: CT chest: Ill defined 10x5mm nodule in RUL is nonspecific and may represent a focus of infection, inflammation or metastatic disease.  1.7 x 2.2 cm right breast soft tissue mass  09/27/19: Follow up with Dr. *****: recommended systemic therapy for locally advanced pancreatic cancer.   10/01/19: Established care with GI medical oncology: recommended FOLFIRINOX for locally adv PDAC  10/22/19: C1D1 FOLFIRINOX ( 5FU 2400mg/m2 over 48 hours, oxaliplatin 85 mg/m2,  irinotecan 180 mg/m2 on day 1, Fulphila and IVF on D3  10/27/19: Pt reported to RN that she'd been having somewhat 
 bloody bm (only after eating), decreased/minimal PO intake, diarrhea with every PO intake since receiving chemotherapy.  She also reported fatigue.  RN advised that pt take Zofran ATC, pick up imodium that had been prescribed, and to increase intake of food, and to report if bloody diarrhea worsened.  10/29/19: Reported continued diarrhea, improved bleeding.  Potassium 2.8, Mg <2, Cr 1.35 and ANC 900.  Received 60 mEQ potassium with IVF, 1g Mg and improvement in K to 3.8, Cr to 0.98. She was sent an Rx for 20mEq PO potassium as well. Advised to take ATC loperamide until no diarrhea x12h  11/05/19: Infusion center for labs notable for K 3.0, Mg 1.3, Cr 1.32. WBC 35. Received 60mEq IV KCL, 1g Magnesium, 1L NS.  Diarrhea had resolved, but still with fatigue, loss of appetite  11/12/19: C2D1 FOLFIRINOX held as pt still recovering--diarrhea had resolved, but she still had poor PO intake, fatigue and preferred to wait an additional week so that she could have support at home.    11/19/19: C2D1 FOLFIRINOX (had been delayed by 1 week for pt recovery per her preference)  12/03/19: C3 FOLFIRINOX delayed per pt preference to have an extra week to recover.  She experienced continued fatigue, loss of appetite diarrhea with C2.    12/10/19: CT CAP: Stable pancreatic mass with vessel encasement, No evidence of distant metastatic disease. Colitis on scans   12/10/19: C3D1 FOLFOX (irinotecan discontinued given evidence of colitis on scans, poor tolerability)  12/24/19: C4D1 FOLFOX (omit irinotecan since C3)    Interval History:  01/07/20: C5D1 FOLFOX  (omit irinotecan since C3)    Today, she presents for follow up and same treatment with C6D1 FOLFOX  -Feels ""almost normal""  -Notes constant saltiness in mouth which limits her appetite, but trying to find foods she likes.  Despite my caution against losing weight, she is have she has lost additional weight and aims to drop to 140lb.  -Denies diarrhea except with fruit  -Notes sensation of 
 throat constriction for D1-7: when drinking room temperature fluids. Not with warm fluids or foods.  Acknowledges that her room is cold and that room temp may still not be warm  -Trying to eat potassium rich foods, would like Klor Con for potassium repletion as she tolerates the size and taste of these pills  -Continued darkening of hands, no neuropathy    Review of Systems:  Systemic: Negative for fevers, chills, or sweats.   fatigue improving, decreased appetite improving, (+) weight loss  Cardiac: Negative for chest pain or palpitations.    Respiratory: Negative for shortness of breath, dyspnea, or cough.    Abdominal: Negative for distension, pain, nausea, vomitin. Resolved bloody diarrhea   Skin: Negative for rash or jaundice.    Musculoskeletal: Negative for bone pain or swelling.   Neurologic: Negative for neuropathy, headaches, blurred vision, or confusion.  Hematologic: Negative for bruising or bleeding.    Psychiatric: Mood is stable.  Patient denies symptoms of anxiety or depression.      All other systems were reviewed and are negative.    Current Medications:  Current Outpatient Medications   Medication Sig Dispense Refill    diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet Take 1 tablet by mouth 4 (four) times daily as needed for Diarrhea 60 tablet 1    EYEBRIGHT ORAL Take by mouth.      gabapentin (NEURONTIN) 300 mg capsule Take 1 capsule (300 mg total) by mouth 3 (three) times daily. 90 capsule 5    glucosam/chond/collagen/hyalur (JOINT SUPPORT ORAL) Take by mouth.      Lactobacillus acidophilus (PROBIOTIC ORAL) Take by mouth.      loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    LORazepam (ATIVAN) 0.5 mg tablet Take 1 tablet (0.5 mg total) by mouth every 8 (eight) hours as needed (nausea) 30 tablet 3    multivitamin tablet Take 1 tablet by mouth daily.      
 ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. 30 tablet 5    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting) 30 tablet 5    acetaminophen (TYLENOL) 500 mg tablet Take 500 mg by mouth every 6 (six) hours as needed for Pain.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. (Patient not taking: Reported on 10/22/2019  ) 30 g 2    oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 10/01/2019  ) 20 tablet 0    potassium chloride (KLOR-CON 10) 10 mEq ER tablet Take 2 tablets (20 mEq total) by mouth daily 60 tablet 3     No current facility-administered medications for this visit.      Facility-Administered Medications Ordered in Other Visits   Medication Dose Route Frequency Provider Last Rate Last Dose    0.9 % sodium chloride infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD        albuterol (PROVENTIL HFA;VENTOLIN HFA) 90 mcg/actuation inhaler 2 puff  2 puff Inhalation Once PRN ***** *****, MD        dextrose 5% infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD 30 mL/hr at 01/21/20 1220 30 mL/hr at 01/21/20 1220    diphenhydrAMINE (BENADRYL) injection 50 mg  50 mg Intravenous Once PRN ***** *****, MD        EPINEPHrine (EPIPEN) injection 0.3 mg  0.3 mg Intramuscular Once PRN ***** *****, MD        fluorouraciL (ADRUCIL) 4,032 mg in sodium chloride 0.9 % 92 mL chemo infusion - for home use  2,400 mg/m2 (Treatment Plan Recorded) Intravenous Once Q46H (Pump) ***** ***** *****, *****        heparin flush 100 unit/mL injection syringe 300 Units  300 Units Intravenous PRN ***** *****, MD        heparin flush 100 
 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** ***** *****, *****   500 Units at 01/21/20 0941    heparin flush 100 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** *****, MD        hydrocortisone sodium succinate (SOLU-CORTEF) 100 mg/2 mL injection 100 mg  100 mg Intravenous Once PRN ***** *****, MD        leucovorin (WELLCOVORIN) 672 mg in dextrose 5% 308 mL infusion  400 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****        LORazepam (ATIVAN) tablet 1 mg  1 mg Oral Once PRN ***** *****, MD        oxaliplatin (ELOXATIN) 142.8 mg in dextrose 5% 579 mL chemo infusion  85 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****           Allergies:  Allergies/Contraindications  No Known Allergies    Past medical, social, and family history were reviewed at today's visit and are unchanged from prior visit.      PHYSICAL EXAM  Vitals:  Vitals    01/21/20 1106   BP: 137/70   Pulse: 94   Resp: 18   Temp: 37.1 C (98.8 F)   SpO2: 97%   Weight: 64 kg (141 lb)   Height: 159 cm (5' 2.6"")   PainSc:  0         Constitutional: Normal appearance. No acute distress. Not ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. No scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is normal. Judgment and thought content normal.   ECOG Performance Status: 1 on 01/21/20    Laboratory Results-reviewed with patient today:    Key elements of latest CBC values... Please see Chart 
 Review for additional result details.  Lab Results   Component Value Date    WBC Count 30.6 (H) 01/21/2020    Hemoglobin 8.7 (L) 01/21/2020    Hematocrit 27.1 (L) 01/21/2020    MCV 99 01/21/2020    Platelet Count 192 01/21/2020     Neutrophil Absolute Count (x10E9/L)   Date Value   01/21/2020 24.06 (H)       Lab Results   Component Value Date    Albumin, Serum / Plasma 4.4 09/24/2019    Alkaline Phosphatase 204 (H) 01/21/2020    Alanine transaminase 22 01/21/2020    Aspartate transaminase 39 01/21/2020    Bilirubin, Total 0.4 01/21/2020    Urea Nitrogen, Serum / Plasma 13 01/21/2020    Calcium, total, Serum / Plasma 8.9 01/21/2020    Chloride, Serum / Plasma 104 01/21/2020    Carbon Dioxide, Total 25 01/21/2020    Anion Gap 12 01/21/2020    Creatinine 1.09 (H) 01/21/2020    eGFR if non-African American 50 01/21/2020    eGFR if African Amer 58 01/21/2020    Glucose, non-fasting 107 01/21/2020    Potassium, Serum / Plasma 2.9 (LL) 01/21/2020    Sodium, Serum / Plasma 141 01/21/2020    Protein, Total, Serum / Plasma 7.7 09/24/2019       Lab Results   Component Value Date    Int'l Normaliz Ratio 1.2 10/15/2019    PT 14.4 10/15/2019       No results found for: HCV, HCVEXL, HCVEXQ, HCVG, HCVRNAQUAL, HCVRNAQUANT, HCVEXT  Lab Results   Component Value Date    HBCAB NEG 10/15/2019    HBSAG NEG 10/15/2019     Cancer Antigen 19-9   Date Value Ref Range Status   01/07/2020 8,274 (H) <38 U/mL Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****).     Carcinoembryonic Antigen   Date Value Ref Range Status   12/10/2019 4.2 <5.1 ug/L Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****).         Imaging Results:    I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:  Ct Abdomen /pelvis With Contrast    Result Date: 
 12/10/2019  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** 8:35 AM CLINICAL HISTORY: Restaging scans. Pancreatic cancer COMPARISON:  CT abdomen/pelvis from 09/24/2019. TECHNIQUE: Following the administration of 150 cc of Omnipaque 350, contiguous 1.25-mm collimation axial images were obtained through the abdomen and pelvis. Coronal and sagittal reformats were also obtained. CONTRAST MEDIA: Intravenous and oral iodinated contrasts were administered. FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Diffuse hepatic steatosis. Heterogeneous and diminished enhancement. Mild intrahepatic biliary ductal dilatation. Gallbladder: Unremarkable Spleen:  Unremarkable Pancreas:  4.4 x 3.5 cm mass in pancreatic body (series 5, image 48), with upstream pancreatic ductal dilatation and parenchymal atrophy, similar to prior study from 09/24/2019. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract: Small hiatal hernia. Diffuse wall edema involving the ascending and transverse colon. No obstruction. Vasculature:  Encasement and obstruction of the portal confluence by the pancreatic mass, with further attenuation of right and left portal veins. Encasement of celiac axis and superior mesenteric artery, with severe stenosis of hepatic artery, splenic artery, as well as superior mesenteric artery. Lymphadenopathy: Several periportal/peripancreatic lymph nodes measuring up to 1 cm, grossly similar to prior study. Peritoneum: Mild edema and trace ascites in upper abdomen. Bladder: Unremarkable Reproductive organs: Unremarkable Bones:  Multilevel degenerative changes in thoracic and lumbar spine, with grade 1 anterolisthesis of L3 on L4 and L4 on L5. Extraperitoneal soft tissues: Substantial interval weight loss. Lines/drains/medical devices: None RADIATION DOSE INDICATORS: Exposure Events: 4 , CTDIvol Min: 12 mGy, CTDIvol Max: 13.4 mGy, 
 DLP: 1012.8 mGy.cm. The following accession numbers are related to this dose report *****,*****     1. Pancreatic mass as detailed above, with encasement and severe narrowing of celiac and superior mesenteric arteries. 2. Ascending and transverse colitis. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Ct Chest With Contrast    Result Date: 12/10/2019  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Cancer metastatic to lung suspected No iodinated contrast contraindication Scan request unrelated to lung cancer Restaging scans. COMPARISON: 09/24/2019 TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. RADIATION DOSE INDICATORS: Exposure Events: 4 , CTDIvol Min: 12 mGy, CTDIvol Max: 13.4 mGy, DLP: 1012.8 mGy.cm. The following accession numbers are related to this dose report *****,***** FINDINGS: LUNGS: Unchanged right upper lobe mixed solid groundglass nodule measuring 1.0 x 0.5 cm (series 14 image 56). Unchanged nodular scar or atelectasis adjacent to the osteophyte in the medial right lower lobe. No new nodules. PLEURA: The pleura is normal. MEDIASTINUM: No intrathoracic lymphadenopathy by CT size criteria. Heterogeneous appearance of the right thyroid gland is unchanged. HEART/GREAT VESSELS: New right chest port with tip in the lower right atrium. Unchanged mild flattening of the ventricular septum which may be due to increased right heart pressures. BONES/SOFT TISSUES: No suspicious bone or soft tissue lesions in the chest. VISIBLE ABDOMEN: Please refer to CT of the abdomen and pelvis reported separately for intra-abdominal findings.     1. No significant interval change in right upper lobe mixed solid and groundglass nodule measuring 1.0 x 0.5 cm. This may reflect scarring, primary lung neoplasm (specifically pulmonary adenocarcinoma), or metastatic disease. 
 Continued surveillance is recommended. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging        Relevant New Pathology:  09/09/19 FNA Pancreatic Tail Mass  A: Pancreas tail mass, Endoscopic ultrasound-guided fine needle  aspiration biopsy: Adenocarcinoma; see comment.  COMMENTS:   The aspirate material shows invasive ductal carcinoma of the pancreas.  Immunohistochemistry was performed to evaluate the status of DNA  mismatch repair protein expression on block A1. The results in the tumor  cell nuclei are:  MLH1 expression: Present.   PMS2 expression: Present.  MSH2 expression: Present.  MSH6 expression: Present.    Impression and Recommendations:  In summary, Ms. ***** is a 73 y.o. female with locally advanced PDAC on mFOLFIRINOX (C1=10/22/19).  She presents for follow up.    Overall plan is for 4-6 months of upfront chemotherapy with q2mo scans. At the end of a period of induction chemotherapy,  we could consider either (1) readdressing her surgical prospects with Dr. *****, although based on her local extent of disease it may be challenging to achieve an R0 resection; or (2)consolidative chemoradiation,either conventionally fractionated therapy with concurrent capecitabine as a radiosensitizer, or SBRT. Of note, for patients who do successful go onto surgery following induction FOLFIRINOX, we have often observed excellent(sometimes near-complete) pathologic responses.     Unfortunately C1 of mFOLFIRINOX on 10/22/19 was complicated by colitis with bloody diarrhea, low ANC, decreased PO intake and hypokalemia requiring 2x IVF in infusion, and addition IV potassium.  I then dose reduced irinotecan to 120mg/m2 for delayed C2 on 11/19/19, and also added Fulphila for growth factor support.  However, this was also poorly tolerated, with persistent fatigue, poor appetite, weight loss. Per her preference, C3 was delayed by 1 week from 
 December 03.  Given her frequent trt delays and rise in CA 19-9 (5000-->11K), I obtained an early look CT CAP on 12/10/19 which fortunately shows stable disease without evidence of distant metastases. It did, however, show colitis, though symptomatically her diarrhea was improving.     As such, I omitted irinotecan with C3.  She has tolerated subsequent cycles of FOLFOX alone quite well.     # Locally Advanced PDAC:   -Labs, PS ok for C6D1 treatment  today, 01/21/20  Omitted irinotecan since C3 (due to colitis on scans, performance status).  Will continue with FOLFOX only going forward:   -oxaliplatin 85mg/m2, 5FU 2400mg/m2 over 46h   -Aloxi, aprepitant, dexamethasone as premeds, with prn ativan D1   -1L NS, 12mg PO dexamethasone, prn Zofran, ativan on D3  -omit D3 Fulphila given ANC >20 today  -Note that pt's CA 19-9 jumped in the setting of colitis.  Improving now   -Plan for scans again after C8, monthly CA 19-9    # Diarrhea: Resolved though exacerbated by certain foods, bl June 14 soft bm.   CT 12/10/19 with evidence of colitis.    --stopped irinotecan with C3.    --couseled regarding BRAT diet, and avoiding dairy for now  --has prn loperamide Rx    # Electrolyte Abnormalities:   -K : 2.9. Plan for 20mEq IV +40mEq PO (with 4x Klor Con 10 mEq pills) on D1.  On D3, will repeat K and Mg: give  20mEq IV +40mEq PO (with 4x Klor Con 10 mEq pills) only if K <=3.3. Hold if >3,3  -Mg 1.5: Receiving 1g today,   --Will send Rx for Klor Con which she prefers dt size-->advised to take 20 mEq daily  -Again, reviewed potassium rich foods (eg bananas, potatoes)  -will consider renal evaluation to r/o RTA as cause of hypokalemia if not improvement    (Note: Previously sent rx for liquid K and MicroK neither of which she has tolerated)    # Weight loss:   -counseled that now is not the time to intentionally lose weight--encouraged her to find foods she enjoys eating, and to maintain weight    # R breast nodule: Recommended diagnostic 
 mammogram  -scheduled for mammogram 11/26/19--cancelled-->will revisit    # Genetic Risk: S/p genetic testing.  VUS in RECQL4 c.*****>G (p.*****)    # Financial Resources:   -- Financial Assistance application approved, now covered.    #Follow Up: 2w      I spent a total of 30 minutes face-to-face with the patient and 30 minutes of that time was spent counseling regarding the treatment plan and symptoms.    The above plan was reviewed with the patient and all questions and issues were addressed to the patient's satisfaction.      ***** ***** MD, MPH  Assistant Professor of Clinical Medicine   Gastrointestinal Oncology Program   University of *****, ***** *****  Office Phone Number: *****-*****-*****   
"
test_2	1	"  FOLLOW UP GASTROINTESTINAL MEDICAL ONCOLOGY VISIT     Patient name  ***** *****    DOB 04/05/1943    Medical record number *****   Date of service 01/31/2022    Referring Provider: Dr. ***** ***** *****        Subjective      ***** ***** is a 78 y.o. male referred by ***** ***** *****, ***** for pancreatic adenocarcinoma located in pancreatic head/unicinate       The history was obtained from the patient, along with my review of all his outside records    History of Present Illness      This pleasant man, hx of aspergillosis, treated with vori now stopped. His recent medical history includes imaging for aspergillosis which revealed a pancreatic mass.    Staging CT scan of the abdomen at that time showed nodal involvement and invasion of the duodenum and abutment of the superior mesenteric vein. partial obstruction is also noted.    *****/*****/*****-*****/*****/*****: UCSF admission for acute symptomatic anemia (s/p transfusion and iron) 2/2 presumed bleed 2/2 pancreatic uncinate adenocarconima with invasion to duodenal wall s/p EGD/EUS with biopsies that showed evidence of adenocarcinoma. After intervention he developed fever with leukocytosis that was attributed to procedure with resolution in absence of abx or further investigation.    *****/*****/*****-*****/*****/*****: Admitted at ***** after presenting to ED with sudden onset respiratory distress, found to have sepsis 2/2 acute on chronic hypoxemic respiratory failure 2/2 R-sided PNA.     04/29/21: Initial consultation with Dr. *****. Patient recommended to initiate FOLFIRINOX. But first patient was recommended to complete C Diff treatment (Vanco), and document neg c diff stool antigen, and then proceed with FOLFIRINOX.    *****/*****/*****-*****/*****/*****: Admitted at ***** for CBD obstruction, gastric outlet obstruction, duodenal obstruction s/p stents to duodenum and CBD with poor PO intake, with course now c/b pancreatitis. Pt underwent EGD/EUS/ERCP 05/06/21 with placement of biliary and duodenal 
 metal stents. Newly identified development of nonocclusive thrombi within the superior mesenteric vein and its branches.     06/03/21: Patient presented for C1D1 Gem/Cape and treatment was held d/t HGB 7.5. Patient refused blood transfusion that day.   06/06/21: Patient received 1 unit PRBC    06/08/21: CT CAP completed d/t increased RUQ pain. IMPRESSION:  - Compared to 05/12/2021, unchanged size of large pancreatic head/unicinate mass. No new suspicious lesions in the abdomen or pelvis.   - Interval resolution of pancreatic inflammatory changes.  - Unchanged position of duodenal and common bile duct stents with further decrease in biliary ductal dilation.   - Suggestion of new rectal wall thickening and hyperemia in the setting of large stool burden and distention that may reflect stercoral colitis.   - Compared to 03/15/2021, slight interval increase in size of mediastinal and bilateral hilar lymph nodes which are borderline enlarged by CT size criteria. Additional apparent increase in patchy groundglass opacities and centrilobular nodules although direct comparison is somewhat limited due to differences in slice thickness between studies. These findings are favored to represent acute infection including viral infection or drug reaction and are similar to although less conspicuous than on more remote prior study from 11/10/2020.    06/09/21: C1D1 Gemcitabine + Capecitabine   06/15/21: Patient fell outside of LabCorp while walking down the stairs  06/23/21: C1D15 Gem/Cape. Labs: HGB 7.9  06/25/21: transfused 1 unit PRBC  07/07/21: C2D1 Gem/Cape   07/21/21: C2D15  08/01/21: CT CAP stable disease   08/04/21: C3D1  08/10/21: Dr.***** presented case at Pancreas tumor board. Dr ***** and Dr. ***** were present. We reviewed images. Not resectable now as SMA involved and tumor low in mesentery. Plan was to evaluate for for Rad Onc for bleeding control.     08/11/21: Consultation with Dr. *****.   Impression: locally advanced pancreas 
 cancer, he is currently unresectable due to extensive vascular involvement at the root of the mesentery.  followup with Dr. ***** regarding continuing systemic regimen vs starting different regimen. Consider radiation.    08/18/21: C3D15 Gem/Cape  08/25/21: Consultation with Dr. *****, Rad Onc. Recommendations:  If they decide to proceed with radiotherapy, we discussed either 5 fraction low dose radiation purely to stop his duodenal bleeding, 5 fraction SBRT for tumor control, or 25 fraction capecitabine-radiotherapy for tumor control.  If SBRT, treatment will be given in 5 treatment sessions over the course of 2 weeks.   We discussed the potential short and long term side effects of radiotherapy, as well as the logistics of radiation, including CT simulation, radiation planning, and actual treatments.  We discussed that with fractionated therapy, we can deliver higher radiation dose to the tumor for potentially better durability of local control, but that no randomized data proves its superiority of SBRT.  At this point, ***** ***** and his daughter did not want to schedule any appointment, preferring first to discuss with Dr. *****.    Plan:  1) Patient uncertain about SBRT vs. Fractionated chemoRT vs new multiagent systemic therapy at this point.  2) No fiducial needed due to involvement of nearby visualizable vessels    09/01/21: C4D1 Gem/Cape   Had one episode of vomiting around 11/08/21.  No hematemesis.   November 22 changed the jejunal stent.   11/10/21 C6D15  Went to ED 12/02/21   XRT  12/08/21--> 12/22/21  12/22/21 ***** (ID) visit: recommended repeat CT scan at some point.   Was given Abx by a pulmonologist recently (~12/23/21)     INTERIM HISTORY  Patient presents for consideration  Fevers episodically around 12/20/21 for a few nights.   12/22/21 pulmonologist gave abx and that seems to have helped.     PAST MEDICAL AND SURGICAL HISTORY  Past Medical History:   Diagnosis Date    Cancer (CMS code)     prostate 
 cancer    Cardiac arrest (CMS code) 2017    Constipation     Mild    COPD (chronic obstructive pulmonary disease) (CMS code)     Diabetes mellitus (CMS code) October 2020    Mild    GERD (gastroesophageal reflux disease) 2000    Hearing loss     Hypertension     Osteoporosis 2018    Moderate    Prostate cancer (CMS code)     Psoriasis        Past Surgical History:   Procedure Laterality Date    EYE SURGERY      IR PORT PLACEMENT (SITE NONSPECIFIC - ORDERABLE BY IR ONLY)  06/01/2021    IR PORT PLACEMENT (SITE NONSPECIFIC - ORDERABLE BY IR ONLY) 06/01/2021 ***** ***** *****, MD RAD IR MZ    prostate cancer surgery      PROSTATE SURGERY         Allergies/Contraindications  No Known Allergies     Current Outpatient Medications   Medication Instructions    acetaminophen (TYLENOL) 325 mg, Oral, Once PRN    bisacodyL (DULCOLAX) 5 mg, Oral, Once PRN    budesonide-glycopyr-formoterol (BREZTRI AEROSPHERE) 160-9-4.8 mcg/actuation INH 2 puffs, Inhalation, 2 times daily    calcium carbonate-vitamin D (OSCAL D) 1,250 mg (500 mg elemental)-200 unit tablet 1 Tbsp, Oral, Every 4 Hours PRN    CALCIUM CITRATE ORAL 1 tablet, Oral, Daily Scheduled    capecitabine (XELODA) 500 mg tablet Take 3 tabs (1500 mg) in the morning with food, take 2 tabs (1000 mg) in the evening with food. Take for 7 days, and then do not take for 7 days.    CREON 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    denosumab (PROLIA) 60 mg, Subcutaneous, See Admin Instructions, Inject 60 mg subcutaneously as directed*****Clinic administered every 6 mos    dronabinoL (MARINOL) 2.5 mg, Oral, 2 Times Daily Before Meals Scheduled, Take 1 hour before breakfast and one hour before dinner.    famotidine (PEPCID ORAL) Oral    GLIMEPIRIDE ORAL 5 mg, Oral, Daily At Bedtime Scheduled    lipase-protease-amylase (CREON) 6,000-19,000 -30,000 unit capsule TAKE 1 CAPSULE BY MOUTH 3 TIMES DAILY WITH MEALS.    melatonin 1 mg 
 tablet Oral, Daily At Bedtime Scheduled    mirtazapine (REMERON) 15 mg tablet TAKE 1 TABLET BY MOUTH EVERYDAY AT BEDTIME    multivitamin tablet 1 tablet, Oral, Daily Scheduled, Brand:  Centrum    ondansetron (ZOFRAN) 8 mg, Oral, Every 8 Hours PRN    pantoprazole (PROTONIX) 40 mg EC tablet Take Pantoprazole 40 ***** tablets, twice daily. Pantoprazole 40 mg tablet 30 minutes before your first meal of the day and 30 minutes before bedtime.    pantoprazole (PROTONIX) 40 mg, Oral, 2 times daily    polyethylene glycol (MIRALAX) 17 g, Oral, Daily Scheduled    prochlorperazine (COMPAZINE) 10 mg, Oral, Every 6 Hours PRN    senna (SENOKOT) 17.2 mg, Oral, Daily At Bedtime Scheduled    sucralfate (CARAFATE) 1 g, Oral, 4 Times Daily Before Meals and Bedtime Scheduled       FAMILY HISTORY  Family History   Problem Relation Name Age of Onset    Hearing loss Mother      Heart disease Mother      High blood pressure Mother      Hearing loss Father      Hearing loss Sister      Hearing loss Brother      Pulmonary fibrosis Neg Hx       Reviewed; no hereditary pattern of cancer noted in the family    PERSONAL AND SOCIAL HISTORY  Social History     Tobacco Use    Smoking status: Former Smoker     Packs/day: 0.50     Years: 28.00     Pack years: 14.00     Types: Cigarettes     Start date: 1990     Quit date: 2008     Years since quitting: 14.8    Smokeless tobacco: Never Used   Substance and Sexual Activity    Alcohol use: Never    Drug use: Never    Sexual activity: Not Currently   Social History Narrative    Immigrated from ***** in 2021    Used to work in business            Objective      Vitals    Flowsheet Row Most Recent Value   Pain Score 0          Wt Readings from Last 3 Encounters:   12/22/21 54 kg (119 lb)   11/29/21 55.3 kg (122 lb)   11/28/21 55.6 kg (122 lb 9.6 oz)      ECOG performance status 2 - Symptomatic, <50% confined to bed  Gen NAD  Able to ambulate in the room without assistance   Respiratory: No 
 respiratory distress, no cough, no use of accessory muscles   LE: No edema  Psych:  appropriate A&O X 3  Neck: full ROM    Review of Prior Testing  Relevant Diagnostic Studies    Lab results   I personally reviewed and interpreted each of the patient's relevant lab tests as outlined in my Assessment/Plan    Lab Results   Component Value Date    WBC Count 8.3 01/31/2022    Abs Neutrophils 3.18 01/31/2022    Hemoglobin 9.7 (L) 01/31/2022    Hematocrit 30.8 (L) 01/31/2022    Platelet Count 241 01/31/2022    Creatinine 0.73 11/24/2021    Bilirubin, Total 0.3 11/24/2021    Alkaline Phosphatase 80 11/24/2021    AST 18 11/24/2021    Alanine transaminase 11 11/24/2021    Albumin, Serum / Plasma 3.0 (L) 11/24/2021    INR 1.1 06/01/2021    Sodium, Serum / Plasma 135 11/24/2021    Potassium, Serum / Plasma 4.0 11/24/2021    Calcium, total, Serum / Plasma 9.4 11/24/2021     Lab Results   Component Value Date    Cancer Antigen 19-9 <2 11/18/2021    Cancer Antigen 19-9 <2 10/27/2021    Cancer Antigen 19-9 <2 06/06/2021       Radiology  I personally reviewed and interpreted each of the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as outlined in my Assessment/Plan     CT Abdomen /Pelvis with and without Contrast    CT Abdomen /Pelvis with Contrast    Result Date: 01/31/2022  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** *****:***** PM CLINICAL HISTORY: Pancreatic adenocarcinoma Restaging scans. COMPARISON:  CT abdomen pelvis 11/18/2021 TECHNIQUE: CT of the abdomen and pelvis was performed. MEDICATIONS: Iohexol 350 - 100 mL - Intravenous FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Persistent mild intrahepatic and extrahepatic biliary dilation with decreased pneumobilia. Similar position of common bile duct stent. Gallbladder: Prior cholecystectomy. Similar fluid in the gallbladder fossa. 
 Spleen:  Unremarkable Pancreas:  Similar size of ill-defined pancreatic mass in the uncinate process, measuring approximately 5.2 x 2.0 cm (series 5, image 72) compared to 5.2 x 2.2 cm on 11/18/2021. Adrenal Glands:  Unremarkable Kidneys:  Contrast in the bilateral collecting systems and ureters. Benign cyst in the right kidney lower pole. GI Tract:  Persistent encasement of the third portion of the duodenum by the pancreatic mass. Similar enhancing soft tissue within the stent, suspicious for tumor (series 5, image 76). Unchanged position of duodenal stent. Interval gastrojejunostomy with axios stent in place. Nondistended stomach. Diverticulosis without findings of acute diverticulitis. Vasculature:  Moderate atherosclerotic disease of the abdominal aorta and its branches. Unchanged obliteration of the superior mesenteric vein at the level of the pancreatic mass. The mass demonstrate similar abutment of the distal superior mesenteric artery. Lymphadenopathy: Similar mesenteric lymph nodes adjacent to the mass, the largest measuring 1.0 cm (series 5, image 68). Peritoneum: No ascites Bladder: Contrast layering dependently in the bladder. Reproductive organs: Unremarkable Bones:  No suspicious lesions Extraperitoneal soft tissues: Similar medium fat-containing left inguinal hernia. Lines/drains/medical devices: As above. RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Min: 6.8 mGy, CTDIvol Max: 6.8 mGy, DLP: 449.1 mGy.cm. The following accession numbers are related to this dose report *****,*****     1.  Similar size of pancreatic mass centered in the uncinate process and invading the duodenum. Similar peripancreatic lymph nodes. 2.  Interval placement of gastrojejunal stent. No findings of proximal obstruction.     CT Chest with Contrast    Result Date: 01/31/2022  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Initial staging COMPARISON: CT chest dated 01/05/2022. TECHNIQUE: Serial 1.25 mm axial images 
 through the chest were obtained after the administration of intravenous contrast. Iohexol 350 - 100 mL - Intravenous RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Min: 6.8 mGy, CTDIvol Max: 6.8 mGy, DLP: 449.1 mGy.cm FINDINGS: Right chest wall port with tip terminating in the superior cavoatrial junction. LUNGS: Overall, slight improvement in waxing and waning multifocal peribronchovascular groundglass, now worse in the right upper lobe and improved in the left upper lobe. Bronchial wall thickening, most notably within the right lower lobe. PLEURA: No pleural effusion or pneumothorax. MEDIASTINUM: Unchanged mediastinal lymph nodes. HEART/GREAT VESSELS: The heart is normal in size without evidence of pericardial effusion. Severe coronary artery atherosclerotic calcifications. Normal caliber thoracic aorta and main pulmonary artery. BONES/SOFT TISSUES: No suspicious osseous lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  Slight improvement in waxing and waning multifocal peribronchovascular groundglass, compatible with an organizing pneumonia pattern of lung injury, which may be secondary to infection or drug reaction. No new or enlarging solid pulmonary nodules. 2. Persistent bronchial wall thickening of the lower lobes, possibly secondary to airway spread of infection. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    CT Chest with Contrast    Result Date: 01/05/2022  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Pancreatic adenocarcinoma hx latent tB, fevers COMPARISON: Thoracic CT from 11/18/2021 and more remote priors TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. Iohexol 350 - 100 mL - Intravenous RADIATION DOSE INDICATORS: Exposure Events: 3 , CTDIvol Max: 4 mGy, DLP: 158.9 mGy.cm FINDINGS: SUPPORT DEVICE(S): Right chest port 
 catheter terminates at the superior cavoatrial junction. LUNGS: Increased upper lobe predominant peribronchovascular groundglass/perilobular opacities. Increased atelectasis in the right middle lobe and lingula. New nodular consolidation in the left lower lobe (series 301, image 364). PLEURA: No pleural effusion. MEDIASTINUM: A few mediastinal nodes have increased in size. For reference, an AP window node measures 0.6 cm in short axis, previously 0.4 cm (series 2, image 96). These are probably reactive to regional inflammation. Mild diffuse esophageal wall thickening, nonspecific. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. Mild coronary artery calcifications. BONES/SOFT TISSUES: No suspicious lesion. VISIBLE ABDOMEN: Increased pneumobilia with intrahepatic and extra hepatic biliary ductal dilation. Thickened, enhancing walls of the hepatic, cystic, and upper common bile ducts, similar to prior exam. Partially imaged common bile duct stent. Several small vessels course along the gastric wall, as seen previously. Partially imaged gastrostomy stent communicating with a left upper quadrant bowel loop. Partially imaged stent within the more posterior lateral aspect of this same bowel loop. Mildly enlarged enhancing node adjacent to the central mesenteric vascular pedicle measuring 1.0 cm in short axis (series 2, image 258). Mild adjacent haziness of the central mesenteric vascular pedicle. Otherwise unremarkable.     1.  Compared 11/18/2021, increased bilateral upper lobe predominant pulmonary opacities compatible with organizing pneumonia pattern lung injury. Considerations include viral infection and/or medication-induced pulmonary injury. 2.  Background of clustered nodules and nodular consolidation compatible with chronic airway infection. 3.  No definite evidence of thoracic metastatic disease. 4.  Increased pneumobilia and biliary ductal dilation. Correlate with laboratory evidence of biliary 
 obstruction if indicated. Report dictated by: ***** *****, MD, signed by: ***** *****, MD Department of Radiology and Biomedical Imaging      I reviewed CT with the patient  I interpret this as stable disease       Pathology  04/19/21 EUS  FINAL PATHOLOGIC DIAGNOSIS    Pancreas, mass, endoscopic ultrasound-guided biopsy: Adenocarcinoma; see comment.     COMMENT:  The biopsy shows infiltrative glands and rare single cells in  desmoplastic stroma.  Marked nuclear pleomorphism and rare foamy  cytoplasm are present, as well as luminal necrosis.  In the context of a  large mass, the findings indicate adenocarcinoma.    Immunostain for DPC4 will be reported by addendum.  UCSF500 molecular testing is in process and will be reported separately.  Drs. *****-*****  *****, ***** *****, and ***** ***** reviewed the H&E slide with  concurrence.  These results were communicated by secure email to Dr. ***** by Dr. ***** on 04/21/2021 at 5:45 p.m.      Genomics  Not done     Assessment and Plan       In summary, ***** ***** is a 78 y.o. male with diagnosed pancreatic adenocarcinoma locally advanced in nature.    C/b SBO s/p stenting    #Pancreatic Adenocarcinoma  - s/p 6 cycles of Gem Cape.   We will consider XRT at this time   we will pause systemic therapy and consider radiation again per patient preference  - Patient does not express CA 19-9     # GIB: due to tumor invasion IMPROVED  - Recommended that he continue to do weekly CBC and transfuse PRBCs PRN for HGB <8.0     #h/o biliary duct obstruction  - s/p biliary metal stent placement 05/06/21  - Continue to monitor alk p/t bil    #h/o small bowel obstruction due to tumor obstruction  - s/p EGD and placement of duodenal stent 05/06/21  - Recommend that he follow low residue diet      #C Diff: treatment completed  # eating and abd pain:  Continue Creon  # Aspergillosis  - Followed by ID, Dr. ***** *****      # ID: ***** latent / Chronic lung infectious 
 process  - Followed by ID, Dr. ***** *****  And ***** Pulm.  -Dr. ***** will do bronch in February after following cultures. He will see him next Tuesday   - Dr. ***** will see him February 17     # protein calorie malnutrition: wt is down to 119 today We discussed ongoing and more aggressive nutritional supplementation  #  Pain  Pain assessment for this encounter  Pain Score/Location    01/31/22 1614   *****:  0    Norco PRN  - Followed by SMS, Dr. *****     #Insomnia  - Followed by SMS, Dr. *****   - Continue Remeron and melatonin as taking now     # nutrition consultation is needed  Pain management plan outlined below as of 01/31/22   Patient denies pain symptoms     Below for Billing purposes only     I reviewed external records from 1 providers outside my specialty or healthcare organization as summarized in the note.  I spent a total of 31 minutes on this patient's care on the day of their visit excluding time spent related to any billed procedures. This time includes time spent with the patient as well as time spent documenting in the medical record, reviewing patient's records and tests, obtaining history, placing orders, communicating with other healthcare professionals, counseling the patient, family, or caregiver, and/or care coordination for the diagnoses above.    I performed this evaluation using real-time telehealth tools, including a live video Zoom connection between my location and the patient's location. Prior to initiating, the patient consented to perform this evaluation using telehealth tools. My location for an independent visit or attending ***** ***** ***** shared visit is not in a UCSF clinical facility.    I reviewed an ID note and a ***** note and ***** care with these teams.     Problems: patient's active cancer represents a life-threatening illness     ***** ***** MD     No orders of the defined types were placed in this encounter.      "
test_3	0	"*****  60 yo F    Chief complaint: Patient with early stage breast cancer here to discuss neoadjuvant therapy    History of Present Illness:  ***** ***** is a 60 y.o. female with a recently diagnosed right sided invasive  spindle cell metaplastic carcinoma breast cancer.    The patient's history began in October 2016 when she felt a mass in her right breast, she sought care at ***** ***** with a breast surgeon 11/30/16, who felt a 3cm mass at 9:00 6cm FN and in the office an US showed a complex cystic mass, she performed a CNB in her clinic    11/30/16: US guided CNB performed: malignant spindle cell carcinoma of the breast, ER neg 0%, PR neg 0%, Her2 FISH neg (ratio 1.2)  12/17/16 Bilateral diagnostic mammo:  L: benign, R: 2.7 cm focal rounded nodular density in the lateral aspect of the right breast, BIRADS 0  12/17/16: US R breast: rounded 2.8 x 1.9 cm area of decreased echogenicity with somewhat variegated internal echotexture. The overall appearance is consistent with a probable postbiopsy hematoma  12/17/16: CXR - nml  12/30/16:MRI breasts performed in *****: irregular mass with heterogenous enhancement and central necrosis (with clip) in 9:00 6cmFN measures 2.9x2.5x3.3. Prominent nodes in Right axillary tail   Left breast with lobulated mass in upper outer quadrant, 7mm    01/15/17: Genetics at ***** - 126 InVitae panel sent  01/15/17: Visit with Dr *****  01/18/17: MRI at *****: 3.5 x 3.2 x 2.6 cm round mass with irregular, slightly spiculated margins and rim enhancement in the outer central right breast, middle depth. Approximately 15 mm anterior to the index mass there is a 12 mm irregular mass enhancing mass. In addition there is another similar 8 mm enhancing mass located 18 mm anterosuperior to the index lesion at the 10 o'clock position.  Taken together the index right breast mass and associated satellite masses span approximately 5.5 cm in AP extent.    IMPRESSION:   Right breast: Known biopsy proven 
 malignancy (BI-RADS 6).  Left breast: Negative (BI-RADS 1).Recommendations:  1) Right outer central breast index malignancy measures 3.5 cm. Two small satellite masses are located 12-15 mm anterior/superior to the index mass.  2) Mildly prominent right axillary lymph nodes. Recommend further evaluation with ultrasound.    02/02/17: PETCT 1. Heterogenous hypermetabolic right breast mass consistent with patient's known breast carcinoma. Associated minimally hypermetabolic non-enlarged bilateral axillary lymph nodes, nonspecific and better evaluated on same day breast MRI. 2. Indeterminate right adrenal nodule measuring up to 2.3 cm. Further evaluation can be obtained with adrenal protocol CT/MRI.     02/02/17: UCSF review of outside path agreed spindle cell metaplastic carcinoma, did not repeat markers, no grade    02/03/17: R US with research cores and placement of clip, FNA axillary node with clip    02/03/17: FNA negative    02/11/17 MRI guided CNB for extent of disease      Cr 1.0 in 2011      The patient has been referred to discuss neoadjuvant treatment.          Past Medical History:   Diagnosis Date    Abnormal liver enzymes 2012    Hyperbilirubinemia    Common bile duct (CBD) stricture 2012    post-chole CBD stricture, presented with acholic stool and dark urine    GERD (gastroesophageal reflux disease)     mild, tums occasionally    HTN (hypertension)     Plantar fasciitis         Gynecologic History:   Menarche was at age 12. Patient is gravida 0 para 0. Patient used oral contraceptives for 0 years. Menopause was at age 57 (3 years of hot flashes). Never used hormone replacement therapy           Past Surgical History:   Procedure Laterality Date    CHOLECYSTECTOMY, LAPAROSCOPIC  2007    Common bile duct stenting  2012    post- Lap chole, placed August 2011, removed 2012    HYSTERECTOMY  1987    for a large fibroid         Current Medications           Current Outpatient 
 Prescriptions   Medication Sig Dispense Refill    clotrimazole-betamethasone (LOTRISONE) 1-0.05 % cream 2 (two) times a day.      ibuprofen (ADVIL,MOTRIN) 800 mg tablet Take 800 mg by mouth once as needed for Pain.      omeprazole (PRILOSEC) 20 mg capsule Take 20 mg by mouth As needed after meals.      triamterene-hydrochlorothiazide (DYAZIDE) 37.5-25 mg capsule Take 1 capsule by mouth Daily.      predniSONE (DELTASONE) 5 mg tablet        No current facility-administered medications for this visit.            Social History:  Social History           Social History    Marital status: Married     Spouse name: N/A    Number of children: N/A    Years of education: N/A           Occupational History    ***** ***** ***** *****     *****         Social History Main Topics    Smoking status: Never Smoker    Smokeless tobacco: None    Alcohol use No    Drug use: No    Sexual activity: No          Other Topics Concern    None         Social History Narrative    Recently divorced    Raised step son from age 3          family history includes Breast cancer in her sister; Cancer (age of onset: 40) in her father; Lung cancer in her paternal grandfather; Stomach cancer in her paternal grandmother.     Review of Systems:   Negative   ROS      Physical Examination:   General appearance - alert, well appearing, and in no distress  Mental status - alert, oriented to person, place, and time  Eyes - sclera anicteric  Neck - supple, no significant adenopathy  Lymphatics - no palpable lymphadenopathy, no hepatosplenomegaly  Chest - clear to auscultation, no wheezes, rales or rhonchi, symmetric air entry  Heart - normal rate, regular rhythm, normal S1, S2, no murmurs, rubs, clicks or gallops  Abdomen - soft, nontender, nondistended, no masses or organomegaly  lap chole scars  Breasts - left breast normal without mass, skin or nipple changes or axillary nodes, abnormal mass palpable in 
 the right breast at 9:00 6cm FN that measures 4x4cm  Neurological - alert, oriented, normal speech, no focal findings or movement disorder noted  Musculoskeletal - no joint tenderness, deformity or swelling  Extremities - peripheral pulses normal, no pedal edema, no clubbing or cyanosis  Skin - normal coloration and turgor, no rashes, no suspicious skin lesions noted    Assessment / Plan:   60 year old female with ER Negative, PR Negative, HER2 Negative right sided breast cancer that is locally advanced, multifocal (possibly awaiting bippsy confirmation of extent of disease). Based on the tumor size and multifocal nature, the patient was referred to discuss neoadjuvant chemotherapy.     We discussed that the metaplastic aspect of her cancer is rare and portends a more aggressive biology - therefore we strongly encouraged neoadjuvant therapy and consideration of the trial with the potential benefit of receiving a promising experimental agent.    We discussed with ***** in great detail the natural history and treatment of locally advanced triple negative breast cancer.  We informed the patient that she currently has no evidence of metastatic disease and that we can therefore treat her with curative intent.  We reviewed the pathology report and discussed the multimodality approach of breast cancer treatment.  The patient understands that treatment will include chemotherapy, surgery, hormonal therapy, and potentially radiation therapy depending on her surgical choice and final pathology.  We discussed the advantages of offering chemotherapy in the neoadjuvant setting in order to assess response to treatment, and to increase the chances of breast conserving surgery.     We discussed the chemotherapy regimens that would be recommended as the standard of care, and discussed how these regimens would be different in the context of the I-SPY2 clinical trial.  We explained that in the context of her higher risk triple 
 negative metaplastic disease we would typically recommend that she receive either 12 cycles of weekly paclitaxel followed by 4 cycles of doxorubicin plus cyclophosphamide (AC) every 2 weeks.  We explained that in the context of I-SPY2, patients are randomized to a control or to receive an experimental agent in addition to paclitaxel.   If she is randomized to an experimental therapy, then we will discuss that drug in more detail at that time.    The patient is very interested in the I-SPY2 clinical trial and has already consented. She has done the MRI, research biopsy, and Echo, mammaprint is pending and the echo looks good.  Her labs revealed an elevated creatinine and Alk phos, and she may have been dehydrated.  We will check these again    We explained that if her tumor has a Mammaprint low risk profile, she would not be eligible to participate in the therapeutic portion of the trial, but given the metaplastic aspect I am fairly certain it will be high risk.  If for some reason it is not, we will need to re-assess the diagnosis of metaplastic breast cancer and we could present her case to our multidisciplinary tumor Board.    We specifically discussed the typical and less common side-effects associated with AC/T, such as fatigue, neuropathy, skin and nail changes, myalgias, alopecia, myelosuppression, nausea.      She will benefit from a Medi-port, which was explained to her and to which she has agreed.  We will arrange for chemo teaching session, and while we could start therapy as early as next week the patient is needing a little more time to arrange things with work and would prefer to start the first week in February which we will plan for.     The patient asked about her genetic predisposition to this cancer - and we will discuss this further with her when we have the results of the gene panel that has been sent.     Pt visit was 55 min, with >50% of the time spent on counseling.     
"
test_4	1	"This is an independent service.  The available consultant for this service is ***** ***** *****, MD.       PATIENT IDENTIFICATION: Mr. ***** is a 53 y.o. male who returns to our GI Oncology practice at the UCSF Comprehensive Cancer Center for follow-up of his diagnosis of adenocarcinoma of the pancreaswith biopsy-proven oligo metastatic disease in the abdominal wall.    ONCOLOGIC HISTORY:   He first presented with abdominal pain and weight loss. On 01/10/2019, he had a CT of the abdomen which showed a mass in the pancreas which encased the celiac axis along with a concerning soft tissue nodule in the abdominal wall at midline.      02/06/19: CT PET showed a hypermetabolically active large pancreatic tail mass abutting adjacent structures, although the lesion in the abdominal wall was slightly PET avid (SUV 1.2).     01/22/19: EUS directed FNA of the pancreatic lesion revealed a diagnosis of adenocarcinoma, MSS.    02/14/19: Biopsy of abdominal wall nodule showed metastatic adenocarcinoma.    03/08/19: Patient presented for C1D1 FOLFIRINOXand labs revealed hyperbilirubinemia (t bili 1.7). Per patient report, he has h/o hyperbilirubinemia and diagnosed ~2 years ago with possible Gilbert syndrome. Irinotecan was held and he proceeded with C1D1 FOLFOX.    03/19/19: C2D1 FOLFIRINOX. T bili was 0.8. Dr. ***** recommended that patient proceed with Irinotecan and closely follow patient for possible irinotecan toxicities.   04/02/19: C3D1 FOLFIRINOX    04/30/19: C4D1 FOLFIRINOX    05/15/19: CT CAP showed stable pancreatic mass and slight decreased size of anterior abdominal wall lesion  05/16/19: C5D1 FOLFIRINOX    05/18/19: US with doppler LE revealed segmental occlusive thrombi within the superior and mid duplicated left peroneal veins. Patient started on xarelto.   05/28/19: C6D1 FOLFIRINOX. CA 19-9 = 2,528    06/11/19: C7D1 FOLFIRINOX    06/25/19: C8D1 FOLFIRINOX. CA 19-9 = 995    07/06/19: CT CAP shows continued 
 response to treatment   07/09/19: C9D1 FOLFIRINOX    07/11/19: CA 19-9 = 588  07/25/19: Treatment held (Cycle 10) d/t thrombocytopenia (PLT 95)  08/01/19: C10D1 FOLFIRINOX. CA 19-9 = 826  08/13/19: C11D1 FOLFIRINOX    09/03/19: C12D1 FOLFIRINOX  (Last cycle)  09/10/19: CT CAP stable disease in the pancreas and abdominal wall lesion. Patient was recommended to start chemotherapy break.     10/03/19: Per patient's request, his case was presented at Pancreas Tumor Board to see if he is a candidate for surgical resection. His pancreas mass is not resectable for multiple reasons, primarily because of extensive vessel involvement and encasement. Dr. ***** ***** recommended consolidation radiation due to the fact that his pancreas tumor is abutting the stomach and concerns over the complications that this will likely lead to. However, Dr. ***** does not recommend radiation therapy at this time since patient is asymptomatic.     INTERVAL HISTORY:   ***** has been feeling generally well. Continues to have some oral thrush. Started fluconazole today. Was also seen by dermatologist recently and started on cicloprox cream for tinea cruris in groin area.     REVIEW OF SYSTEMS:   14 point ROS completed and all other systems were reviewed and are negative.    Current Outpatient Medications   Medication Sig Dispense Refill    butenafine (LOTRIMIN ULTRA) 1 % cream       cholecalciferol, vitamin D3, 1000 UNITS TAB tablet Take 4 tablets by mouth daily         clotrimazole (MYCELEX) 10 mg troche 1 tablet (10 mg total) by Other route 3 (three) times daily Take by buccal route. Take for 14 days and during chemotherapy cycles after initial treatment 90 Troche 1    fluconazole (DIFLUCAN) 100 mg tablet Take 200mg PO qd on day one followed by 100mg PO qd on subsequent days.  Take for 1 week and then stop. 8 tablet 0    hyoscyamine (LEVSIN/SL) 0.125 MG SL tablet Place 1 tablet (0.125 mg total) under the tongue every 4 (four) hours as needed 
 (abdominal cramping). (Patient not taking: Reported on 09/17/2019  ) 60 tablet 3    KERYDIN 5 % SolA       L.acidoph/B.long/L.plant/B.lac (PROBIOTIC ACIDOPHILUS BEADS ORAL) Take by mouth.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. 30 g 2    lipase-protease-amylase (CREON) 24,000-76,000 -120,000 unit capsule Take 2 tabs with meals and 1 tab with snacks. 300 capsule 5    loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    medical cannabis       ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. (Patient not taking: Reported on 07/25/2019  ) 30 tablet 5    oxyCODONE (OXYCONTIN) 10 mg 12 hr ER tablet Take 1 tablet (10 mg total) by mouth every 12 (twelve) hours (Patient not taking: Reported on 09/17/2019  ) 60 tablet 0    oxyCODONE (ROXICODONE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 4 (four) hours as needed for Pain (for moderate to severe pain). (Patient not taking: Reported on 09/17/2019  ) 90 tablet 0    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting). (Patient not taking: Reported on 09/17/2019  ) 30 tablet 5    rivaroxaban (XARELTO) 20 mg tablet Take 1 tablet (20 mg total) by mouth daily 30 tablet 5    terbinafine HCl (LAMISIL) 1 % cream Apply topically Daily. Use as instructed      TURMERIC ORAL Take by mouth      UNABLE TO FIND Take 1 tablet by mouth Host Defense brand ""Stamets 7"" Daily Immune Support, one tablet every other day during weeks of no infusion.   Each tablet contains 71.5 mg of royal sun blazei, cordyceps, reishi, maitake, lion's mane, chaga, and mesima.        UNABLE TO FIND Take by mouth Host 
 Defense brand Turkey Tail extract, ~ 0.5 ml every other day during weeks of no infusion       No current facility-administered medications for this visit.        ALLERGIES:  Allergies/Contraindications  No Known Allergies    Past medical, social, and family history were reviewed at today's visit and are unchanged from prior visit.      PHYSICAL EXAM:  Objective   Vital Signs:   There were no vitals filed for this visit.  ECOG Performance Status: 1 - Symptomatic but completely ambulatory  Constitutional:  WDWN, NAD, pleasant and conversant   Eyes: sclera anicteric  Respiratory: no respiratory distress  Neurologic: Alert & oriented x 3  Psychiatric: Mood stable. No HI, SI, hallucinations, paranoia, or delusions.    DIAGNOSTIC STUDIES:   Laboratory data:   Lab Results   Component Value Date    WBC Count 6.4 09/03/2019    Neutrophil Absolute Count 4.18 09/03/2019    Hemoglobin 11.4 (L) 09/03/2019    Hematocrit 35.4 (L) 09/03/2019    Platelet Count 126 (L) 09/03/2019    Creatinine 0.74 09/03/2019    Bilirubin, Total 0.4 09/03/2019    Alkaline Phosphatase 160 (H) 09/03/2019    Aspartate transaminase 31 09/03/2019    Alanine transaminase 30 09/03/2019    Albumin, Serum / Plasma 3.7 04/26/2019    Int'l Normaliz Ratio 1.1 03/05/2019    Sodium, Serum / Plasma 134 (L) 04/26/2019    Potassium, Serum / Plasma 3.9 04/26/2019    Calcium, total, Serum / Plasma 9.1 04/26/2019     Lab Results   Component Value Date    Cancer Antigen 19-9 576 (H) 08/27/2019    Cancer Antigen 19-9 826 (H) 08/01/2019    Cancer Antigen 19-9 588 (H) 07/11/2019    Carcinoembryonic Antigen 16.2 (H) 08/27/2019    Carcinoembryonic Antigen 11.7 (H) 08/01/2019    Carcinoembryonic Antigen 17.0 (H) 07/11/2019     Foundation Medicine liquid biopsy results:   MSI Status Undetermined  RB1 P26fs*47      ASSESSMENT AND PLAN:   In summary, Mr. ***** is a 53 y.o. male who returns to our GI Oncology practice at the UCSF Comprehensive Cancer Center for follow-up of his 
 diagnosis of adenocarcinoma of the pancreaswith biopsy-proven oligo metastatic disease in the abdominal wall. He is now s/p 12 cycles of FOLFIRINOX.    #Stage IV pancreatic adenocarcinoma  Patient has completed 12 cycles of FOLFIRINOX from February 2019 - August 2019, and is currently on chemotherapy break. He has restaging CT planned for 11/19/19.    During today's visit I reviewed with ***** the Pancreas Tumor Board's recommendations. I explained why surgical resection is not recommended. Also discussed the role of palliative radiation therapy to his pancreas mass and why Dr. ***** has not recommended radiation at this time. I also reviewed signs and symptoms of a GI bleed and other complications that could arise if his pancreas tumor where to invade into the stomach.     Foundation Medicine liquid biopsy results:   MSI Status Undetermined  RB1 P26fs*47    #Thrush: Ongoing  - SMS recommended fluconazole.   - Will also have patient complete labs to rule out diabetes (he has h/o prediabetes): blood glucose and Hemboglobin A1C    #occlusive thrombi within the superior and mid duplicated left peroneal veins  -  Continue xarelto QD    #Abdominal pain/cramping: Improved  - Followed by SMS, Dr. ***** *****   - Continue Creon to 2 or 3 tab/meal and 1 tab/snack   - Cont Oxycontin 10mg PO bid  - Oxycodone 5 to 10mg PO q4h prn BTP (can cut 10mg tabs in half)    #Weight loss: Improved  - Followed by Cancer Center Nutritionist ***** *****, *****    #Supportive care   - followed by  SMS, Dr. *****    Advance Care Planning   Discussed with: ***** *****, NP     Surrogate decision maker: Identified and documented: ***** ***** (1st); ***** ***** (2nd)    Life sustaining treatment preferences (i.e. Code): DNR and Unknown    Additional preferences of care (eg: Goals; Fears and worries; Sources of strength; Critical abilities; Trade-offs; Family): Relevant values/priorities: Mental capacity, free of pain    Changes to treatment 
 plan as a result of this conversation: Preferences for life sustaining treatment clarified and POLST completed     RTC: 11/21/19 to see Dr. ***** or sooner if indicated    As always, the patient was counseled to contact the clinic or the after-hours physician on call for any new symptoms or complications in the interim between now and her follow up visit with me. Thank you for involving me in the care of this very kind patient.  Please do not hesitate to contact me with any questions or concerns.    I spent a total of 25 minutes face-to-face with the patient and >50% of that time was spent counseling regarding the symptoms, treatment plan, risks and/or therapeutic options for the diagnoses above.    I performed this consultation using real-time Telehealth tools, including a live video connection between my location and the patient's location. Prior to initiating the consultation, I obtained informed verbal consent to perform this consultation using Telehealth tools and answered all the questions about the Telehealth interaction.    ***** *****, NP    
"
test_5	0	"SUBJECTIVE    ***** ***** is a 49 y.o. female with ER+/PR-/HER2- left breast cancer, mammaprint low risk IDC of the left breast s/p NAHT, s/p bilateral mastectomies, s/p adjuvant tamoxifen *****/*****-*****/*****. She was switched to OS/AI in November 2018. Switched from letrozole to exemestane December 2018 due to anxiety and emotional lability.      Interval History  Attempted letrozole for August 12.5 months but switched to exemestane after experiencing anxiety and mood swings. Tolerating exemestane better.   +minimal joint aches  +mild hot flashes and insomnia  +bone pain  +vaginal dryness    Recently graduated from master's program so has more time now to exercise.    No new or concerning bone pain, sob, cough, abd pain, n/v, headache, visual changes    ROS  All systems reviewed and negative except for as outlined above in the HPI.        Past Medical History:   Diagnosis Date    Breast cancer (HCC)     Endometriosis     Malignant neoplasm of left female breast (HCC) 01/10/2017    PONV (postoperative nausea and vomiting)        Patient Active Problem List    Diagnosis Date Noted    Malignant neoplasm of female breast (HCC) 11/12/2017     Added automatically from request for surgery *****      Status post bilateral mastectomy 07/18/2017    S/P mastectomy, bilateral 05/27/2017     Added automatically from request for surgery *****      Postoperative visit 05/27/2017     Added automatically from request for surgery *****      Wound disruption, post-op, skin, sequela 05/27/2017     Added automatically from request for surgery *****      Breast cancer, left (HCC) 04/09/2017    PONV (postoperative nausea and vomiting) 03/27/2017    Malignant neoplasm of left female breast (HCC) 01/10/2017     Clinical stage 2-3 HR+ HER2 negative IDC on NAHT     -12/05/16: Screening mammo - Extremely dense. LEFT 3:30, 5 cm FN: 1.8cm irregular spiculated mass with overlying skin retraction.  LEFT 3:30, 2.5 cm FN: 1.3cm irregular spiculated mass. LEFT 
 inner retroareolar: Small benign appearing oval circumscribed masses measuring up to 1.3 cm. RIGHT inner retroareolar: Multiple oval circumscribed masses measuring up to 3cm.  -12/05/16: Bilateral US (converted from screening to diagnostic):  LEFT 3:30, 5cm FN: 1.8 x 1.1 x 0.9cm irregular spiculated hypoechoic mass, highly suspicious. LEFT 3:30, 2.5cm FN: 0.8 x 0.9 x 1.3cm irregular spiculated mass, highly suspicious. Few small cysts. No left axillary adenopathy. RIGHT 11:00, 4cm FN: 0.9 x 0.6 x 0.5cm oval mass with microlobulated margins (originally better seen on ABUS but confirmed on focused US). RIGHT inner retroareolar additional benign appearing oval circumscribed masses including cysts measuring up to 3cm.  Pathology:  LEFT 3:30, 5cm FN (1.8cm mass): IDC. Grade 2. No LVI. l0 mm on core. ER 61-70%. PR negative. Ki-6715-20%. Her-2 negative by FISH  HER2 negative by FISH.  LEFT 3:30, 2.5cm FN (1.3cm mass): IDC. Grade 3. No LVI. 15 mm on core. ER 41-50%. PR 1-10%. Ki-67 30-40%.  HER2 negative by FISH. +LCIS focally.  RIGHT 11:00. 4cm FN (0.9cm mass): Sclerosing adenosis, negative for CA. Felt to be concordant.  -12/22/16: MRI breast - LEFT posterior lateral mass measures 2.4 x 2.5 x 2.9cm, abuts but does not invade the pectoralis major. Extends to within 2mm of overlying skin which is abnormally thickened and retracted, though no abnormal skin enhancement. LEFT anterior-medial smaller mass measures 1.6 x 1.3x 1.5cm. Highly suspicious lower outer (3:30-5:30) segmental nonmass enhancement inferior, medial and between both masses spanning a region 3.6 x 4.2 x 3cm. Few small inner left breast cysts. No axillary adenopathy. RIGHT breast with multiple cysts measuring up to 2.5cm in the outer breast and 3.lcm in the inner breast.  -01/06/17: Mammaprint - low  -01/08/17: CT CAP -  Enhancing mass in the left breast, no axillary, hilar, mammary LAD.  No distant mets  -01/10/17: MRI  LEFT Breast:  1) Index tumor: There are 
 two adjacent irregular masses with spiculated margins in the lower outer left breast, posterior depth, best seen on post gad axial image 77/***** and sagittal *****/*****, with a biopsy clip centered in each mass. Signal intensity/time curve demonstrates rapid initial rise and washout enhancement kinetics.    2) Additionally, there is asymmetric non-mass enhancement extending medially from the two index masses, concerning for DCIS. The overall span of the two adjacent masses and NME measures 34 x 32 x 28 mm.    3) There is a 5 mm oval mass in the outer central left breast, anterior depth, best seen on post gad axial image 66/*****. Signal intensity/time curve demonstrates rapid initial rise and washout enhancement kinetics. This mass is approximately 2 cm anterosuperior to the index masses.    RIGHT Breast:  1) There are 2 adjacent foci in the upper outer right breast, anterior depth. One is 4mm and is best seen on post gad axial image 57/*****. Signal intensity/time curve demonstrates rapid initial rise and plateau enhancement kinetics. The other is 3 mm and is best seen on post gad axial image 55/*****. Signal intensity/time curve demonstrates medium initial rise and persistent enhancement kinetics.    2) There is a post biopsy clip in the outer central right breast, middle depth, site of biopsy proven sclerosing adenosis, which was sampled at an outside facility. There is non-mass enhancement just medial to the biopsy clip, best seen on post gad axial image 69/*****, which is likely represents the sclerosing adenosis.  01/11/17: start tamoxifen    01/18/17: start zoladex injection    February 2017: switch from tamoxifen to letrozole  March 2017: d/c letrozole and switch back to tamoxifen September 13 depression  04/09/17:  bilateral mastectomies and left slnb: path pending  November 2018: stopped tamoxifen, switch to OS/letrozole    December 2018: switched from letrozle to exemestane due to anxiety and emotional lability, cont zoladex locally monthly        
 Polycystic ovaries 12/26/2016     Last Assessment & Plan:   Long history of amenorrhea, in the last year, they have increased to almost monthly.  Now, increased pain with ovulation and periods, they are heavier and clotting.       Cyst of breast 06/16/2015     Last Assessment & Plan:   HISTORY/REASON FOR EXAM: 2 left breast lumps noted on self breast examination.  TECHNIQUE/EXAM DESCRIPTION: Unilateral LEFT digital diagnostic mammography was performed and interpreted with CAD, limited left breast ultrasound.  COMPARISON: 11/26/14 and 06/01/09.  FINDINGS:  3 views of the left breast were obtained.  The breast tissue is extremely dense.  There are is a large rounded benign-appearing nodule in the inferior medial periareolar region of the left breast at the site of one lump.  There is dense breast parenchyma in the lateral mid anterior portion of the left breast at the site of a second lump which was marked.  No spiculated mass or suspicious calcification is identified.  Limited left breast ultrasound: There is a large cyst containing one thin partial septation located at the 10:30 position 1 cm from the nipple measuring 3.9 x 3.0 x 2.1 cm. This accounts for one of the 2 palpable nodules.  There is a small simple cyst at the 3:00 position 3 cm from the nipple measuring 4.2 x 3.8 x 3.3 mm. This accounts for the second palpable nodule.  No solid nodule is present.  IMPRESSION:  1. 2 simple cysts in the left breast accounting for the palpable abnormalities.  2. Cyst aspiration of the larger cyst could be performed if pain persists.  3. If symptoms resolve routine bilateral followup mammography in November 2015 is recommended.  The results were given to the patient at the time of visit.      Mass of breast 05/12/2015     Last Assessment & Plan:   mammo done November 2014.      1. BREASTS ARE EXTREMELY DENSE, WHICH LOWERS SENSITIVITY OF MAMMOGRAPHY. NO GROSS EVIDENCE OF MALIGNANCY AND NO INTERVAL CHANGE.    2. SCREENING MAMMOGRAM 
 IN ONE YEAR IS RECOMMENDED.    Recently found a couple of lumps left breast.  No nipple discharge.  Some discomfort left breast      Neck pain 05/12/2015     Last Assessment & Plan:   Had a MVA last  *****.  Went to ***** ***** ***** for workup.  She recalls imaging as negative.  She continues to have neck pain radiating to left shoulder.  Underwent PT, this made it worse.  She is undergoing rolfing and would like to try some muscle relaxers to take prior to the sessions.  Numbness and tingling in left arm.  Her hand will shake with weight.  Her arm symptoms predated the MVA.  She was seen by the ***** for this complaint just before the MVA.       Anxiety disorder 01/12/2015       MEDICATIONS  Current Outpatient Medications   Medication Sig Dispense Refill    amoxicillin (AMOXIL) 875 mg tablet TAKE 1 TABLET BY MOUTH TWICE A DAY UNTIL GONE  0    amoxicillin-clavulanate (AUGMENTIN) 875-125 mg tablet Take by mouth.      benzonatate (TESSALON) 200 mg capsule Take 200 mg by mouth.      buPROPion (WELLBUTRIN XL) 150 mg 24 hr tablet Take 150 mg by mouth.      doxycycline (VIBRA-TABS) 100 mg tablet TAKE 1 TABLET BY MOUTH TWICE A DAY FOR 10 DAYS  0    exemestane (AROMASIN) 25 mg tablet TAKE 1 TABLET BY MOUTH EVERY DAY FOR 30 DAYS  4    HYDROcodone-acetaminophen (NORCO) 5-325 mg tablet TAKE 1 TO 2 TABS BY MOUTH EVERY 6 HOURS AS NEEDED FOR PAIN *G89*  0    IBU 800 mg tablet TAKE 1 TABLET BY MOUTH EVERY 8 HOURS AS NEEDED  3    metroNIDAZOLE (METROGEL) 0.75 % gel Apply thin film to affected area BID      ondansetron (ZOFRAN-ODT) 4 mg rapid dissolve tablet DISSOLVE 1 TAB ON THE TONGUE EVERY 6 HOURS AS NEEDED FOR NAUSEA/VOMITING  0     No current facility-administered medications for this visit.        ALLERGIES    Allergies/Contraindications   Allergen Reactions    Latex Hives    Venom-Honey Bee Anaphylaxis    Penicillins Hives    Codeine Nausea Only       PHYSICAL EXAM  Vital signs:   Vitals:    01/21/19 1252 
   BP: 117/66   Pulse: 75   Resp: 18   Temp: 37 C (98.6 F)   TempSrc: Temporal   SpO2: 100%   Weight: 64.2 kg (141 lb 9.6 oz)   Height: 162.9 cm (5' 4.13"")     ECOG: 0  Physical Examination: General appearance - alert, well appearing, and in no distress  Mental status - alert, oriented to person, place, and time  Eyes - pupils equal and reactive, extraocular eye movements intact  Mouth - mucous membranes moist, pharynx normal without lesions  Neck - supple, no significant adenopathy  Lymphatics - no suspicious cervical, SC, axillary lymphadenopathy  Chest - clear to auscultation, no wheezes, rales or rhonchi, symmetric air entry  Heart - normal rate, regular rhythm, normal S1, S2, no murmurs, rubs, clicks or gallops  Abdomen - soft, nontender, nondistended, no masses or organomegaly  Breasts -s/p bilateral mastectomies with implants. No suspicious masses, nodules, rashes bilaterally   Back exam - full range of motion, no tenderness, palpable spasm or pain on motion  Neurological - alert, oriented, normal speech, no focal findings or movement disorder noted  Musculoskeletal - no joint tenderness, deformity or swelling  Extremities - peripheral pulses normal, no pedal edema, no clubbing or cyanosis  Skin - normal coloration and turgor, no rashes, no suspicious skin lesions noted      RESULTS  None to review    ASSESSMENT & PLAN  ***** ***** is a 49 y.o. female with  ER+/PR-/HER2- left breast cancer, mammaprint low risk IDC of the left breast s/p NAHT with tamoxifen, s/p bilateral mastectomies, s/p adjuvant tamoxifen *****/*****-*****/*****, switched to OS/letrozole in November 2018 but switched from letrozole to exemestane in December 2018 due to anxiety and emotional lability.       1. Breast Cancer  -NED on exam  -Continue exemestane 25mg daily. We discussed continuing AI for at least 5 years.   -Recommend checking estradiol level to ensure ovarian suppression, if suppressed can check q3months  -needs DEXA scan now and every 2 years. If 
 osteopenia can consider adding bisphosphonate. Reviewed adjuvant bisphosphonate data showing reduced distant mets, improved BCSS, and OS for postmenopausal women and bisphosphonate use.   -she is considering BSO which is reasonable since she will likely be in natural menopause after 5 years of OS/AI.  -continue q6months exams, no imaging given bilateral mastectomies    2. Depression/Anxiety, improved  -Follow up with local psych for ongoing support as needed.      Follow-up in 6 months or sooner if she has new or worsening symptoms.     I have reviewed and updated the patient's past medical history, medications, allergies, family and social histories. I spent a total of 40 minutes face-to-face with the patient and 30 minutes of that time was spent counseling regarding the treatment plan, symptoms and therapeutic options. Patient expresses understanding and agrees with the plan.    *****, ***** *****, am acting as a scribe for services provided by ***** ***** *****, MD on *****/*****/***** 11:46 AM      The above scribed documentation as annotated by me accurately reflects the services I have provided.   ***** ***** *****, MD  *****/*****/***** 11:51 AM      
"
test_6	0	"HPI:  ***** ***** is a 34 y.o. female here in consultation to discuss treatment options for her newly diagnosed breast cancer whose history is as follows:    Patient Active Problem List    Diagnosis Date Noted    Breast Cancer Right 04/25/2019     December 2018 self-palpated right breast mass  03/05/2019 Bilateral breast US (***** ***** Hospital in *****): 6x7 mm mass with ductal extension at 1 o'clock, likely DCIS.   03/17/2019 Gynecology at ***** for lower abdomen swelling, urethral discomfort and breast mass in the breast US (*****). On exam 1 cm firm, mobile, nontender mass approximately 5 cm from nipple at 1 o'clock.  03/17/2019: Right breast FNA at 1 o'clock (*****): Benign and could be seen in the setting of fibrocystic change or fibroadenoma.  03/17/2018 Abdomen-pelvic CT: No acute findings (for abdominal pain).  03/28/2019 Bilateral breast diagnostic mammogram (*****): A focal asymmetry is suggested in the region. Triangular marker denotes site of focal pain in the lower slightly outer right breast, with no underlying mammographic correlate. Scattered and occasionally grouped benign-appearing microcalcifications, both breasts, predominantly coarse dystrophic, likely the sequelae of reported fat grafting.  03/28/2019 Bilateral breast diagnostic US(*****): 22 x 10 x 15 mm oval complex solid and cystic mass with peripheral echogenicity and an irregular, antiparallel hypoechoic central component in the right upper inner quadrant, 1:00, 8 cm from nipple. The central hypoechoic component measures up to 10 mm. No sonographic correlate to site of focal pain in the lower outer right breast at 7 o'clock, 5 cm from nipple. No sonographic correlate to clinician's site of concern in the left axilla. A few normal-appearing nodes are identified. Left breast: benign  03/30/2019 Right breast US guided core biopsy at 1 o'clock 8 cm from nipple (UCSF): Grade 1 IDC, ER+(>95%), PR(~90% ranging from weak to strong nuclear staining), HER2 
 equivocal(IHC 2), FISH non-amplified (0.55 cm largest dimension in a core; multiple core involved), Ki-67: ~10%. Focal atypical ductal hyperplasia. Pseudoangiomatous stromal hyperplasia. DCIS not present.  04/24/2019 Dr. ***** at *****. genetics referral   04/24/2019 Dr. ***** at *****: discussed bilateral TSSM with expander/implant reconstruction  04/25/2019 Dr. ***** (Surgeon) discussed surgical options lumpectomy vs bilateral mastectomy, recommended genetic testing.  04/25/2019 Myriad Genetic Result: Negative  05/08/2019 Dr. ***** (***** *****) planned double mastectomy with reconstruction with Dr. ***** ***** (*****)  05/24/2019 Mammaprint (Agendia): Low risk: +0.287      Family history of Alzheimer's disease 04/25/2019    Bipolar 2 disorder (HCC) 04/04/2019    Insomnia 04/04/2019     Pathology report from 03/30/19 shows she has ER+/PR+ and HER2 equivocal IDC of the right breast. Recently had a bilateral breast MRI on April 24.    Notes she has been drinking more wine recently due to the Shelter-in-Place orders, 1-3 glasses 5x a week.     She is planning on attending ***** ***** at ***** *****.      Past Medical History:   Diagnosis Date    Allergy 2010    Seasonal    Anxiety     Bilateral ovarian cysts     Bipolar II disorder (HCC)     diagnosed mid 20's, controlled on lamictal    Hemorrhoids 2012    Invasive ductal carcinoma of right breast in female (HCC) 04/04/2019    Invasive Ductal carcinoma     Past Surgical History:   Procedure Laterality Date    BLEPHAROPLASTY Bilateral 11/14/2018    BREAST BIOPSY      Fat transfer  2019    breast and face    labialplasty  2015    LIPOSUCTION  2015    abd, thighs, flanks, buttocks, trunk - fat transfer to breast/fat and sculpting    REFRACTIVE SURGERY Bilateral      Family History   Problem Relation Name Age of Onset    Rashes / Skin problems Maternal Aunt      Hypertension Mother      Other (smoking) Mother      Hypertension Maternal Uncle      Diabetes 
 Paternal Uncle      Hypertension Paternal Uncle      Rheum arthritis Maternal Grandmother      Diabetes Maternal Grandmother      Hypertension Maternal Grandmother      Colon cancer Maternal Grandmother          dx L60's to E70's    Diabetes Maternal Grandfather      Heart disease Maternal Grandfather      Hypertension Maternal Grandfather      Migraines Paternal Grandmother      Diabetes Paternal Grandfather      Alzheimer's disease Paternal Grandfather      Alzheimer's disease Paternal Great-Grandfather      Breast cancer Maternal Aunt ***** ***** 40        Lobular carcinoma, 40 bilateral (in situ)    Breast cancer Maternal Aunt ***** ***** 55        DCIS, 55    Other (smoker) Father      Melanoma Neg Hx      Basal cell carcinoma Neg Hx      Squamous cell carcinoma Neg Hx      Skin ca. unk/oth Neg Hx       Allergies/Contraindications   Allergen Reactions    Latex Itching     IRRITATION  Sensitivity- causes tender skin and skin irritation    Aripiprazole      Suicidal ideation  depression  Suicidal ideation    Lurasidone      Suicidal ideation       Social History     Patient does not qualify to have social determinant information on file (likely too young).   Social History Narrative    Travelled for work for ***** as a ***** and ***** *****, then came back to ***** with the COVID pandemic    Had been planning to go to ***** school in *****    Now plans to complete her undergraduate school in the ***** *****    Also has worked as a ***** ***** ***** and *****  *****    Lives with her aunt and uncle in ***** ***** ***** right now    OCPs for 5 years, stopped with diagnosis    G1TAB1         Current Outpatient Medications:     ascorbic acid, vitamin C, 500 mg TABSR, Take by mouth daily., Disp: , Rfl:     B-complex with vitamin C tablet, Take by mouth daily., Disp: , Rfl:     clonazePAM (KLONOPIN) 1 mg tablet, Take 1 tablet (1 mg total) by mouth nightly as needed for Anxiety 
 (Insomnia)., Disp: 5 tablet, Rfl: 3    KAVA ROOT ORAL, Take by mouth. Kava tincture-  Use 1/2 -1 teaspoon by mouth Kava for anxiety, Disp: , Rfl:     Lactobacillus acidophilus (PROBIOTIC ORAL), Take 1 capsule by mouth. PROBIOTIC-10PO, Disp: , Rfl:     lamoTRIgine (LAMICTAL XR) 200 mg 24 hr ER tablet, Take 1 tablet (200 mg total) by mouth daily., Disp: 30 tablet, Rfl: 0    multivitamin capsule, Take 1 capsule by mouth daily. Multiple Vitamin, Disp: , Rfl:     multivitamin-Ca-iron-minerals TAB, Take 1 tablet by mouth., Disp: , Rfl:     tretinoin microspheres (RETIN-A MICRO PUMP) 0.08 % GlwP, Apply 1 Application topically Daily., Disp: 50 g, Rfl: 5    TURMERIC ORAL, Take 1 capsule by mouth. TURMERIC PO take 1 cap by mouth daily, Disp: , Rfl:     UNABLE TO FIND, Med Name: ELDERBERRY PO take by mouth daily., Disp: , Rfl:     zolpidem (AMBIEN) 5 mg tablet, Take 1 tablet (5 mg total) by mouth nightly as needed for Sleep, Disp: 5 tablet, Rfl: 0    Review of Systems - All other systems were reviewed and are negative except that outlined above.    BP 110/75 (BP Location: Left upper arm, Patient Position: Sitting, Cuff Size: Adult) Comment: vitals after visit | Pulse 52  | Temp 36 C (96.8 F) (Temporal)  | Resp 16  | Wt 61.5 kg (135 lb 9.6 oz) Comment: w/shoes | SpO2 100%  | BMI 23.61 kg/m   Physical Examination: General appearance - alert, well appearing, and in no distress  Mental status - alert, oriented to person, place, and time  Eyes - Right eyelid stye, upper lid pupils equal and reactive, extraocular eye movements intact  Mouth - mucous membranes moist, pharynx normal without lesions  Neck - supple, no significant adenopathy  Lymphatics - no palpable lymphadenopathy  Chest - clear to auscultation, no wheezes, rales or rhonchi, symmetric air entry  Heart - normal rate, regular rhythm, normal S1, S2, no murmurs, rubs, clicks or gallops  Abdomen - soft, nontender, nondistended, no masses or 
 organomegaly  Breasts - 2 cm R breast mass 8 cm from the nipple   Back exam - full range of motion, no tenderness, palpable spasm or pain on motion  Neurological - alert, oriented, normal speech, no focal findings or movement disorder noted  Musculoskeletal - no joint tenderness, deformity or swelling  Extremities - peripheral pulses normal, no pedal edema, no clubbing or cyanosis  Skin - normal coloration and turgor, no rashes, no suspicious skin lesions noted  Tatoo left upper shoulder and left abdomen     I personally reviewed and interpreted the following results:  Results for orders placed or performed in visit on 03/17/19   Syphilis Screen by RPR with Reflex to Treponemal Antibody   Result Value Ref Range    Syphilis Screen by RPR with Reflex to Treponemal Antibody Nonreactive Nonreactive   HIV Ag/Ab Combo   Result Value Ref Range    HIV Ag/Ab Combo NEG NEG       Assessment and Plan:    Patient Active Problem List   Diagnosis    Bipolar 2 disorder (HCC)    Insomnia    Breast Cancer Right    Family history of Alzheimer's disease   IMP  34 year old premenopausal woman with 1 to 2.2 cm grade 1 IDC, strongly ER and PR positive, and mammaprint low risk.  Diagnosis made in March and surgery has been delayed due to COVID19.  Unclear when Dr. ***** and ***** will be able to do surgery at *****.  I have talked with Dr. ***** and as of today, the date is unknown.  She has been offered surgery at *****, but would prefer to stick with this team of surgeons.    We discussed the biology of her cancer, and the prevalence.  We reviewed the imaging and her pathology in detail.  I reviewed the data that supports the use of ovarian suppression in woman with HR+ breast cancer under the age of 35, as the general duration of endocrine therapy which at present would be 5 years.  She was curious about the benefits relatively of shorter duration endocrine therapy , and whether two years would be good enough - and we 
 reviewed that the current studies are based on the knowledge that 5 years is not good enough for many cancers like this due to late recurrence risks, so we would not advise shorter durations.    We then talked about different endocrine therapy approaches.  I would be concerned about using tamoxifen alone, both for efficacy which what appears to be at least a 2 cm cancer on exam and for the risks of depression that could be difficult given her underlying bipolar II disorder.    We discussed to toxicities of OS with monthly goserelin, as well as the toxicities of tamoxifen versus an AI.  She would prefer to start with an AI, and I have told her that we will wait two weeks to at least have OS start working.  I also advised her about the menses that often occur two weeks after starting OS    Plan  Start goserelin today (no auth required!)  Start letrozole in about two weeks  Message sent to *****. ***** to discuss surgery timing  Discussed lumpectomy versus mastectomy; she is certain about bilateral mastectomy with reconstruction  Hot soaks to stye  Labs today including estradiol    We talked about treatment of hot flashes and she will ask her psychiatrist about the interaction of effexor and gabapentin and her lamictal and underlying bipolar II disorder.    RTC one month depending on plans for surgery.    Patient ready and able to be educated, verbalizes understanding of information/instructions given.  Treatment options, side effects and nutrition reviewed in detail.  Total face to face time: 75  Total counseling time: 60    *****, ***** ***** am acting as a scribe for services provided by ***** *****. *****, MD on *****/*****/***** *****:***** PM    The above scribed documentation accurately reflects the services I have provided.    ***** *****. *****, MD   *****/*****/***** *****:***** PM          
"
test_7	1	"SUBJECTIVE:    This is a very pleasant 47-year-old African-American gentleman with a diagnosis of locally advanced adenocarcinoma of the pancreas. He presented with several months of vague abdominal discomfort and had some gross hematuria in September. He went to ***** Hospital and a CT scan was done which revealed a pancreatic mass. His hematuria was felt to be secondary to renal lithiasis. This problem resolved.    He was noted to have biliary obstruction and underwent an ERCP with an EUS at ***** on October 24. A plastic stent was placed. Fine-needle aspiration of the mass revealed adenocarcinoma.    When I initially saw him, he had lost 43 pounds and was having a lot of pain. We elected to start gemcitabine and Abraxane. He's completed 6 full cycles. At the end of 2 cycles, his CT scan suggested progression. However, since he was doing so well clinically, we felt that this represented pseudo-progression.    His 5th cycle treatment was interrupted because of biliary ductal obstruction. He had a plastic stent was replaced with an uncovered metal stent. Apparently there was a lot of pus and material that drained at the time of that procedure and he was placed on IV and oral antibiotics. Since the procedure, he has had intermittent abdominal discomfort, usually at night, requiring oxycodone.     He feels that his appetite has returned. He's gained kilogram last month. He notices some numbness and tingling in his hands but it doesn't interfere with his function. He is having regular bowel movements.    He would like to meet with psycho oncology as he is having some difficulty coping with his disease and with some social and economic issues.    His girlfriend gave birth to a baby girl on April 27.     PAST MEDICAL HISTORY:     MEDICAL ILLNESSES:  Hypertension, voluntarily stopped his antihypertensive    PRIOR SURGERIES:  Drainage of a perirectal abscess, age 17    INJURIES:  None reported    CURRENT MEDICATIONS:  See 
 intake    ALLERGIES:  Allergies   Allergen Reactions    Penicillins Hives       FAMILY HISTORY:  There is no cancer among his first-degree relatives. He has 2 siblings. His maternal grandmother had colorectal cancer diagnosed at age 55. A paternal grandmother may have colorectal cancer, age of diagnosis uncertain.    SOCIAL HISTORY:  He smoked about a half a pack of cigarettes per day for about 4 years, quitting in 2006. There is a prior history of alcohol abuse where he drank up to a pint of tequila day, but he has been drinking only socially more recently. He has a past history of heroin abuse, but has not used for several years.   He is accompanied by his mother ***** who works as a *****'***** ***** and his sister ***** who is an administrative *****.      PE:    Vitals:   Vitals: BP 131/90 | Pulse 64 | Temp 36.9 C (98.5 F) (Oral)  | Resp 20 | Ht 182 cm (5' 11.65"") Comment: October 2015 | Wt 94.3 kg (208 lb) | SpO2 100% | BMI 28.48 kg/m2   In general, he appears comfortable.  HEENT no icterus      LABORATORY RESULTS:  Results for orders placed or performed during the hospital encounter of 05/28/16   Complete Blood Count with 5-part Differential   Result Value Ref Range    WBC Count 6.7 3.4 - 10 x10E9/L    RBC Count 3.89 (L) 4.4 - 5.9 x10E12/L    Hemoglobin 11.1 (L) 13.6 - 17.5 g/dL    Hematocrit 33.5 (L) 41 - 53 %    MCV 86 80 - 100 fL    MCH 28.5 26 - 34 pg    MCHC 33.1 31 - 36 g/dL    Platelet Count 203 140 - 450 x10E9/L    Neutrophil Absolute Count 4.06 1.8 - 6.8 x10E9/L    Lymphocyte Abs Cnt 1.49 1.0 - 3.4 x10E9/L    Monocyte Abs Count 0.84 (H) 0.2 - 0.8 x10E9/L    Eosinophil Abs Ct 0.23 0.0 - 0.4 x10E9/L    Basophil Abs Count 0.02 0.0 - 0.1 x10E9/L    Imm Gran, Left Shift 0.02 <0.1 x10E9/L   Urea Nitrogen, Serum / Plasma   Result Value Ref Range    Urea Nitrogen, Serum / Plasma 13 6 - 22 mg/dL   Creatinine, Serum / Plasma   Result Value Ref Range    Creatinine 1.06 0.61 - 1.24 mg/dL    eGFR if non-African 
 American 83 >60 mL/min    eGFR if African Amer 96 >60 mL/min   Aspartate Transaminase   Result Value Ref Range    Aspartate transaminase 20 17 - 42 U/L   Alanine Transaminase   Result Value Ref Range    Alanine transaminase 25 12 - 60 U/L   Bilirubin, Total   Result Value Ref Range    Bilirubin, Total 0.9 0.2 - 1.3 mg/dL   Alkaline Phosphatase   Result Value Ref Range    Alkaline Phosphatase 60 31 - 95 U/L   Cancer Antigen 19-9   Result Value Ref Range    Cancer Antigen 19-9 3 <36 U/mL       IMAGING:  Ct Abdomen /pelvis With Contrast    Result Date: 06/10/2016  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** *****:***** PM CLINICAL HISTORY: 48-year-old male with pancreatic cancer COMPARISON:  01/28/2016 CT abdomen pelvis, 03/18/2016 CT RADIATION DOSE INDICATORS: ***** ***** received 2 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are: Event: 1;  anatomic area: Chest;  phantom: body;  CTDIvol: 14.2;  DLP: 533.3 Event: 2;  anatomic area: Chest;  phantom: body;  CTDIvol: 18.8;  DLP: 888.6 The following accession numbers are related to this dose report [*****]: ***** The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on ""Computed Tomography (CT)"" or go to *****://*****.*****.*****.*****/*****/*****. TECHNIQUE: Following the administration of 150 cc of Omnipaque 350, contiguous 1.25-mm collimation axial 
 images were obtained through the abdomen and pelvis. The gastrointestinal tract was opacified with oral and rectal  contrast. Coronal and sagittal reformats were also obtained. FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Bones:  No suspicious lesions Liver:  6 mm hypervascular lesion in hepatic segment 8 which may reflect flash filling hemangioma or portosystemic shunt, unchanged from prior No significant intrahepatic biliary duct dilatation. Gallbladder:  Unremarkable Spleen:  Unremarkable Pancreas:  Redemonstration of ill-defined hypoattenuating mass centered in the pancreatic head, extending to the pancreatic tail, and involving the portosplenic confluence and superior mesenteric vein. Although difficult to measure this appears minimally increased in size and appears prior. Minimally decreased pancreatic duct dilatation to 7 mm in the pancreatic tail. The stent has been changed in courses from the common hepatic duct into the duodenum persistent pneumobilia suggests patency. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract:  No bowel obstruction. Pancreatic mass continues to abut the duodenum, unchanged from prior. Vasculature: No significant change in vascular involvement. Lymphadenopathy: Small mesenteric and retroperitoneal nodes, none of which are enlarged by size criteria. Ascites: Absent Bladder: Unremarkable Reproductive organs: Unremarkable Extraperitoneal soft tissues: Unremarkable     1.  Stable to minimally increased size of pancreatic mass compatible with known pancreatic adenocarcinoma. 2.  No evidence of metastatic disease in the abdomen/pelvis. END OF IMPRESSION:     Ct Chest With Contrast    Result Date: 06/10/2016  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Panceatic cancer COMPARISON: 03/18/2016 and earlier TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the 
 administration of intravenous contrast. RADIATION DOSE INDICATORS: ***** ***** received 2 exposure event(s) (excluding scout) during this CT study. The CTDIvol (mGy) and DLP (mGy-cm) radiation dose values for each event are: Event: 1;  anatomic area: Chest;  phantom: body;  CTDIvol: 14.2;  DLP: 533.3 Event: 2;  anatomic area: Chest;  phantom: body;  CTDIvol: 18.8;  DLP: 888.6 The following accession numbers are related to this dose report [*****]: ***** The dose indicators for CT are the volume Computed Tomography Dose Index (CTDIvol) and the Dose Length Product (DLP), and are measured in units of mGy and mGy-cm, respectively. These indicators are not patient dose, but values generated from the CT scanner acquisition factors.  Individual patient doses calculated from these values will depend on patient size and can substantially underestimate or overestimate the actual dose. For additional information on radiation dose, safety, and protection in the UCSF Department of Radiology and Biomedical Imaging, please refer to one of our FAQ leaflets on ""Computed Tomography (CT)"" or go to *****://*****.*****.*****.*****/*****/*****. FINDINGS: LUNGS: Few new small nodules in the left lower lobe measuring up to 3 mm (series 2, images 121, 138, 166, 170) and a 7 mm new nodule in the lingula. Previously noted tiny nodule in the peripheral right upper lobe (prior study series 2, image 90) is not visualized on this exam. Right middle lobe nodule is unchanged (series 2, image 129). PLEURA: No pleural effusion. MEDIASTINUM: 8 mm lymph node adjacent to the inferior vena cava (previously 7 mm; series 2, image 179). No lymphadenopathy by size criteria. HEART/GREAT VESSELS: Normal heart size. No pericardial effusion. BONES/SOFT TISSUES: No suspicious lesions. VISIBLE ABDOMEN: Please see dedicated Abdomen and Pelvis CT report.     1.  5 new nodules measuring up to 7 mm in the lingula and left lower lobe. These are indeterminate 
 but are suspicious for metastases in the setting of known pancreatic adenocarcinoma. Attention on follow-up. 2.  No other definite evidence of metastatic disease in the chest. END OF IMPRESSION:       ASSESSMENT:  1. Locally advanced adenocarcinoma of the pancreas, with possible progression  2. Hypertension  3. Possible cancer family syndrome  4. ECOG 0     PLAN:    The new lung nodules are concerning but these are unlikely to become a problem for him. He would really like a chemotherapy break. This seems reasonable since he appears to have received maximum benefit on this regimen. Given the sites of disease involvement and his lack of symptoms, I think it would be safe to put him on surveillance. We'll see him again in 2 months for follow-up. I spent 20 minutes in face-to-face consultation with the patient and his mother today going over all aspects of his care and management.    
"
